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Cystic fibrosis (CF) is the most common life-limiting genetic disorder in the 
United States, and is characterized by progressive obstructive lung disease. The severity 
of lung disease can be highly variable even among individuals with identical mutations in 
the disease-causing gene, CFTR. Half of the variation in CF lung function is attributable 
to environmental/stochastic factors, thus identifying environmental factors that affect 
lung function is crucial in ameliorating the disease burden.  
Using data from the CF Twin-Sibling Study and two national registries, we 
previously demonstrated that warmer annual ambient temperatures were associated with 
lower lung function after adjusting for CFTR genotype and demographic/environmental 
factors. However, the mechanisms behind this association remain to be elucidated. Thus, 
the objectives of this thesis were to identify mechanisms by which ambient temperature 
affects lung function, specifically through assessments of common CF respiratory 
pathogens using databases of subjects with CF (Chapter 2), tests for gene-environment 
interactions using genomic data from the CF Twin-Sibling Study (Chapter 3), and 
assessment of whether this phenomenon exists in the general population using NHANES 
databases (Chapter 4).  
Taken together, the results from Chapters 2 and 4 of this study potentially explain 
40-83% of the association between lower lung function and warmer temperatures in CF 
and identify some mechanisms that underlie this association. The mediation analyses in 
Chapter 2 in two separate populations of individuals with CF ascribed 12-43% of the 
association in CF to 3 respiratory pathogens. Chapter 4 also confirmed the presence of 
this association within the general population with effect sizes of 0.7% and 1.0% 
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predicted FEV1 decrease for every 10°F increase in mean annual ambient temperature in 
the two NHANES general population cohorts and suggested that 28-40% of the 
association seen in CF can be ascribed to a mechanism also present in the general 
population. Chapter 3 did not identify any specific gene-environment interactions with 
genetic modifiers of CF lung disease or genetic modifiers of lung function in the general 
population. Our results have important implications for both individuals with CF with 
respect to their healthcare and the general population with respect to population health 
and climate change. 
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CHAPTER 1. INTRODUCTION 
Section 1.1. Cystic Fibrosis 
 Cystic 




over 30,000 people 
in the United States 
and over 70,000 
worldwide (www.cff.org). Although therapeutic advances have dramatically increased 
the median age of survival (Figure 1.1), life expectancy is still approximately half that of 
the general population. The underlying genetic defect in cystic fibrosis was identified in 
1989 and consists of mutations in the CFTR (Cystic Fibrosis Transmembrane 
conductance Regulator) gene on chromosome 7, an ABC transporter class chloride ion 
channel found in epithelial cells.1 Over 2000 mutations in this gene have been reported 
(http://www.genet.sickkids.on.ca), however not all of these mutations are disease causing 
(e.g., p.Met470Val). Specific mutations are correlated with certain aspects of disease 
severity, such as pancreatic insufficiency, but not others, such as lung function.2-4 
Inheritance is mediated in an autosomal recessive manner; carriers are generally 
asymptomatic. Given the prevalence of carriers in the population (1:30 U.S. Caucasians), 
mutations are suspected to have a heterozygote advantage, but the specific evolutionary 





















Figure 1.1. Estimated Median Age of Survival (U.S.) 
in Cystic Fibrosis; data from U.S. CF Foundation
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 Clinically, cystic fibrosis manifests in multiple epithelial organs (Figure 1.2) as 
the mutated channel protein is produced in reduced numbers, degraded more rapidly, or 
functions poorly, leading to thickened secretions. Blockage of pancreatic ducts and 
subsequent injury leads to exocrine and endocrine pancreatic disease, resulting 
malabsorption, malnutrition, and diabetes. Thick respiratory secretions that are poorly 
cleared from the lung and sinuses lead to colonization by respiratory pathogens resulting 
in acute episodes of bronchitis, pneumonia, and sinusitis, as well as chronic, progressive 
lung disease. It is the latter decline in lung function that currently results in 90% of the 
mortality seen in this disorder. The milieu of respiratory organisms colonizing the airway 
does change with age (Figure 1.3), with certain organisms, such as Pseudomonas 
aeruginosa,8,9 Burkholderia cepacia complex,10-12 and methicillin-resistant 
Staphylococcus aureus (MRSA)13-15 being associated with worse prognosis.  
Figure 1.2. Common Manifestations of Cystic Fibrosis 
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Figure 1.3. Common Respiratory Pathogens in CF by Age (From the U.S. CF 
Foundation Patient Registry 2011 Report) 
 
 As is seen in Figure 1.3, given enough time, most people with CF are colonized 
with P. aeruginosa. Current standard of care is to attempt eradication at the first positive 
culture for P. aeruginosa. Once P. aeruginosa colonizes the respiratory tract, it 
frequently mutates into a “mucoid” strain, which confers the organism certain protection 
to clearance.16,17 Other disease manifestations of cystic fibrosis include meconium ileus, 
nasal polyps, cirrhotic liver disease, and male infertility owing to absence of the vas 
deferens.  
 Optimal care for people with CF in the U.S. currently includes a minimum of 4 
visits annually at an accredited or affiliate CF center with a multidisciplinary team, which 
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may consist of a physician (frequently a pulmonologist), nutritionist, respiratory 
therapist, social worker, CF nurse or case manager, physical therapist, pharmacist, and 
psychologist. At these routine visits, spirometry is obtained as a measure of lung function 
and respiratory cultures (expectorated sputum or throat swab) are obtained for qualitative 
surveillance. These data can serve as longitudinal measures for clinical research studies. 
With regards to lung function, it is more likely that spirometry measures underestimate 
true lung function owing to inadequate patient effort, poor technique, or illness, rather 
than overestimate. With regards to respiratory cultures, throat swabs, in particular, may 
not accurately represent lower respiratory flora.18,19 
 In terms of maintenance therapies, most people with CF have exocrine pancreatic 
insufficiency from birth and require pancreatic enzymatic supplements with every meal, 
snack, and/or supplemental tube feed. Most people with CF also require a complex 
regimen of airway clearance consisting of vibrating chest vests, aerosolized medications, 
etc. to aid with clearing the lower airways of thick secretions. They may also be receiving 
prophylactic antibiotics to decrease bacterial load in the airways. Estimates suggest that 
completing all recommended therapies may require at least 1-2 hours daily, a significant 
burden for patients and their families.20 
 People with CF often experience respiratory exacerbations that manifest with 
fevers, increased cough, sputum production, weight loss, wheezing, increased fatigue, 
and/or an abrupt decline in lung function. Typical management includes increased 
frequency of airway clearance and either oral or intravenous antibiotics. Although 
patients do regain some lung function after an exacerbation, they frequently do not return 
to their pre-exacerbation baseline.21 
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 Lastly, care is continuing to improve with innovative new therapies.22,23 In 
January 2012, the U.S. Food and Drug Administration approved the first medication, 
ivacaftor, to target the defect of CF. Although the FDA-approved indications for use of 
the CFTR potentiator ivacaftor includes ten CFTR mutations,24 these mutations account 
for a small fraction of the CF population.25 The use of drugs such as ivacaftor and other 
CFTR potentiators and correctors is expanding. For example, the combination of 
ivacaftor and the corrector lumacaftor for patients homozygous for the most common 
CFTR mutation, F508del, was just approved in July 2015.26 
Section 1.2. Research Significance 
Cystic fibrosis (CF) is the most common life-limiting genetic disorder in the 
United States, affecting over 30,000 individuals. Despite advances in nutritional and 
respiratory care, the median age of survival in 2013 (40.7 years) was approximately half 
that of the general population. Clinically, CF is characterized by chronic progressive 
obstructive lung disease, which is responsible for the majority of morbidity and mortality 
associated with this disorder. Progressive lung disease is accelerated by recurrent 
respiratory infections with irrevocable loss of lung function despite effective therapy for 
symptoms.21,27 Although the causal gene, the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene, has been known for over 20 years,1 it has become evident that 
significant variation in the severity CF lung disease exists even among individuals with 
identical mutations.2-4 Twin and sibling studies of lung function in individuals with CF 
indicate that approximately half of the variation in lung function is attributable to genetic 
factors, but half is due to environmental and/or stochastic (random) factors.28-30  
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As survival is correlated with severity of lung disease,31,32 understanding the 
environmental factors that affect lung function is crucial in ameliorating the disease and 
financial burden imposed by CF. Although a number of studies have demonstrated 
associations between lung function and individual environmental factors, including 
secondhand smoke exposure,33-37 air pollution,38 household income,31-33 maternal 
education,39 and insurance status,39-42 limited analyses have been performed to determine 
the relative contribution of these factors.39,43 Furthermore, most studies have focused on 
environmental factors operating at a household level. With the exception of air 
pollution,38 there has been limited work examining environmental factors operating on a 
geographic scale, such as climate. 
Using data from the U.S. CF Twin-Sibling Study, we previously demonstrated 
that warmer annual ambient temperatures were associated with lower lung function; we 
subsequently independently replicated this finding in two national registries in the United 
States and Australia.44 We also tested the contribution of temperature relative to other 
environmental factors, and found that temperature remained significantly associated with 
lung function even after adjusting for CFTR genotype, demographic factors, socio-
economic factors, and other geographic factors, such as relative humidity. The 
mechanisms by which temperature affects lung function in individuals with CF remain to 
be elucidated.  
Ambient temperature has been demonstrated to be associated with the prevalence 
of both infectious and non-infectious diseases,45 particularly with vector-borne infectious 
diseases; however, our replicated association between ambient temperature and lung 
function is novel. Studying this association may yield new insights into the mechanisms 
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by which geographic factors, such as climate, affect human health, and may have 
ramifications for informing healthcare policy. Thus, this thesis may inform our 
knowledge of CF respiratory physiology and may increase our understanding of the 
epidemiology of common CF respiratory pathogens (Chapter 2), may identify gene-
environment interactions which may contribute to the development of CF lung disease 
(Chapter 3), and may improve our understanding of respiratory pathophysiology in the 
general population (Chapter 4). 
More specifically in Chapter 2, the expected findings will allow respiratory and 
infectious clinical outcomes from study sites and CF centers across a wide geographic 
area to be more accurately compared without temperature bias. The clinical care of 
patients with CF has benefited from one of the first disease-specific data registries, the 
U.S. Cystic Fibrosis Foundation Patient Registry. Benchmarking using aggregate data by 
individual CF care centers by the U.S. CF Foundation Patient Registry has spurred on 
widespread efforts for quality improvement. Based on our preliminary data, we would 
estimate a hypothetical 18 year old male with CF (Height: 175cm; Non-Hispanic White) 
with an NHANES46 FEV1 of 73.5% percent living in a climate with colder temperatures 
would be expected to have an FEV1 of 66.1% had he resided in a 30 degree (°F) warmer 
climate, which would be a clinically relevant difference in lung function. Given that 
annual ambient temperature is not within patients’ and clinical providers’ control, 
geography may need to be considered when patients, clinicians, and payers compare the 
performance of different CF Care Centers. Furthermore, ambient temperature may also 
need to be considered in the design of multi-center CF studies of lung function as well as 
clinical trials that encompass broad geographic areas. Because of these considerations 
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and the ongoing need to improve outcomes, it is important to determine by which means 
temperature affects lung function as this may lead to improved means of risk 
stratification and determining clinical trajectories. It is possible that information from this 
study may guide regionally based initiatives or management strategies to improve 
outcomes as well.  
This study represents one of the first efforts to identify gene-environment 
interactions with a replicated environmental modifier of lung function (i.e., temperature) 
that operates on a geographic scale. The proposed work may serve to inform other similar 
efforts. More specifically, in Chapter 3, identifying modifier gene-temperature 
interactions would provide pilot data to explore why such significant variation in CF lung 
disease exists among individuals with identical CFTR mutations, and will allow future 
tests of genetic modifiers to be more accurately interpreted in light of a patient's 
geographic location.  
Lastly in Chapter 4, the knowledge of whether temperature is associated with lung 
function in the general population may inform our understanding of pathophysiology of 
lung disease not only for CF patients, but also for lung function in the general population 
and among other individuals with obstructive lung diseases, such as asthma and COPD. 
Section 1.3. Approach for Chapter 2 
To identify (a) which common respiratory pathogens in CF are associated with 
temperature and (b) the extent to which these organisms explain the relationship between 
temperature and lung function.  
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Introduction: Determining factors that influence the acquisition and the timing of 
acquisition of pathogens is essential step in improving outcomes for individuals with CF. 
Owing in part to impaired airway clearance, acute infections and colonization with 
respiratory pathogens are common in CF. Specific respiratory pathogens that have been 
demonstrated to result in lower lung function or increased mortality in CF include 
Pseudomonas aeruginosa,8,9 Burkholderia cepacia complex,10-12 and methicillin-resistant 
Staphylococcus aureus (MRSA).13-15 Furthermore, earlier acquisition of, at least, P. 
aeruginosa as detected on respiratory cultures is associated with the development of more 
severe lung disease.47 
The objective of Chapter 2 is to determine which respiratory pathogens in CF are 
associated with temperature and if associations between temperature and infection exist, 
whether they explain the association between temperature and lung function. Assessing 
the association between temperature and infection will be accomplished through 
multivariate regression. The contribution of any such association to lung function will be 
assessed through mediation analysis.48,49 The primary study population will be derived 
from the U.S. Twin-Sibling Study with replication in the CF Foundation Patient Registry. 
Preliminary Data: Our preliminary data demonstrated an association between 
warmer temperatures and lower lung function in three independent samples of individuals 
with CF (Table 1.1). Samples were derived from the U.S. CF Twin-Sibling Study, the 
U.S. CF Foundation Patient Registry, and the Australian CF Data Registry. Associations 
between temperature and lung function were tested for using stepwise linear regression 
clustered for family (Twin-Sibling Study) or CF care center (U.S. Registry). The adjusted 
regression coefficients indicated that lung function is ~3 percentile points lower for every 
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10°F increase in annual ambient temperature. As an example, there is a 30°F difference 
in mean annual temperature between Florida and Maine. This association was 
independent of socio-economic factors such as insurance status or estimated household 
income as well as CFTR genotype as measured by number of F508del alleles. The 
association seen in the Twin-Sibling Study sample was replicated in the U.S. Registry 
sample. The association trended towards significance in the Australian Registry sample 
and the 95% C.I. did overlap the estimates from the U.S. populations. Differences 
between the analyses in the United States versus Australia may be secondary to a reduced 
absolute range of temperatures in Australia or a shift in Australia to warmer temperatures. 
 
Table 1.1. Preliminary Data: Higher Ambient Temperatures are Associated with Lower 






U.S. CF Registry Australian CF 
Registry 
N 1313 15174 1791 
Adjusted Co-efficient for 







Temperature Co-efficient p Value 0.005 <0.001 0.057 
*Regressions were adjusted for insurance status and age at the time of pulmonary function testing in the U.S. samples, 
and age for the Australian sample. 
Preliminary data also demonstrated an association between a higher prevalence of 
a significant CF respiratory pathogen, Pseudomonas aeruginosa, and warmer ambient 
temperature (Table 1.2). Independent samples of subjects with CF included the previous 
three samples as well as a prospectively recruited sample from Australia and New 
Zealand through the Australian CF BAL (ACFBAL) study. These associations persisted 
even after adjustment for CFTR genotype, age at time of last respiratory culture, and age 
at diagnosis. In addition, an earlier age of acquisition of P. aeruginosa was observed with 
warmer temperatures in the two populations where longitudinal data were present (Twin-
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Sibling Study, ACFBAL). The mean ages of acquisition were younger in the ACFBAL 
study compared to Twin-Sibling Study likely owing to ascertainment method differences. 
Specifically, the ACFBAL study included a complete record of respiratory cultures from 
early infancy as well as the more frequent use of bronchoscopy to obtain lower airway 
culture samples, which may be more sensitive than the typical throat swabs used in 
routine clinical collection as in the Twin-Sibling Study. It is also possible that the 
younger ages of acquisition seen in the ACFBAL study may reflect just an earlier age of 
acquisition unique to Australasia. No association with temperature was seen with mucoid 
P. aeruginosa (Twin-Sibling Study) or Burkholderia cepacia complex (Twin-Sibling 
Study, U.S. and Australian Registries).  
Table 1.2. Preliminary Data: Higher Annual Ambient Temperatures are Associated with 
a Higher Prevalence and Earlier Age of Acquisition of P. aeruginosa 
   Stratification by Temperature Quartiles 
(°F) 
 
Variable Study Sample 
 
N 











> 58.1 - 
















































To examine the relationship between infection with P. aeruginosa, temperature, 
and lung function, we performed mediation analysis. As can be seen in Table 1.3, the 
inclusion of P. aeruginosa in the models of lung function resulted in a decrease in the 
magnitude of the coefficient for temperature in all three study populations. The relative 
decrease in the magnitude of the coefficient for temperature is the portion of the 
association between temperature and lung function that could be ascribed to P. 
aeruginosa (Twin-Sibling Study: 15%; U.S. Registry: 6%; Australian Registry: 22%). It 
should be noted that these results could also represent confounding by another 
unmeasured variable or collider-stratification bias. 
Table 1.3. Preliminary Data: Regression Analyses for Lung Function: Assessing the 
Mediation Effect of P. aeruginosa* 






Model with  
P. aeruginosa 
Base Model 

















































*Insurance status and age at the time of pulmonary function testing were also significant predictors of lung function for 
both U.S. samples, but not the Australian Registry sample. 
Study populations: Although more detailed study population descriptions will be 
included in the relevant sections of Chapters 2, 3, and, 4, a brief summary of these 
populations follows (Table 1.4).  
Cystic Fibrosis Twin-Sibling Study: The dataset included 1730 geocoded 
individuals with pulmonary function test and respiratory culture data. The study is based 
at Johns Hopkins University (PI: Dr. Garry Cutting) and has recruited families primarily 
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from the U.S. between 2000 and 2013. It is estimated that ~90% of the twins with CF and 
~60% of the siblings with CF in the U.S. have been recruited. Collected data included 
questionnaires including environmental exposures, clinical data including respiratory 
cultures and pulmonary function tests, and DNA (blood) samples. Clinical and 
environmental data for subjects receiving care from U.S. CF care centers are 
supplemented on an annual basis using data from the U.S. CF Foundation Patient 
Registry. The last update covered through calendar year 2011.  
U.S. CF Foundation Patient Registry: The U.S. Registry is a partnership between 
patients, CF care centers, and the CF Foundation to collect clinical and environmental 
data on almost all patients receiving care at CF care centers in the U.S. This patient 
registry represents the largest database of individuals with CF in the world. The data used 
in this study included a download of the relevant de-identified data for the calendar year 
2007, comprising 24,799 individuals. Subjects recruited in the Twin-Sibling Study 
population were excluded from analyses using the U.S. Registry population. The dataset 





Table 1.4. Study Sample Details 
 CF Twin-
Sibling Study 













√   
Chapter 4 (General 
Population) 





√ √ √ 
Genetic Data √   
Clinical Data Cross-Sectional 
Lung Function Data 
√ √ √ 
Longitudinal Lung 
Function Data 








√ Not available Not applicable 
 
Temperature Data: A mean annual ambient temperature was assigned to each 
subject based on their residential zip code. Temperatures used were 30 year averages of 
annual temperatures (1981-2010) obtained from The Climate Source (Corvallis, OR). 
Although recent climate change may have increased these average temperatures for the 
more recent period in which lung function was collected, it was expected that temperature 
increases would be similar for all subjects. The use of multiple years of temperature data 
was employed to minimize year-to-year variation in temperature. These climate data were 
used for both CF study populations as well as the NHANES study population. 
Lung Function Data: Forced expiratory volume in 1 second (FEV1) is a 
spirometric measurement obtained at routine and sick visits at CF centers. FEV1 was used 
as the measure of lung function for this proposal as it is closely correlated with survival 
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among CF patients.31,32 Raw FEV1 (liters) measurements were not used for this study as 
both children and adults were included in analyses, thus raw measurements were 
converted into CF-specific percentiles, which account for age, sex, and body size 
(height).50 Measurements obtained before 6 years of age and after lung transplantation 
were excluded as measurements obtained under the age of 6 years are frequently less 
reproducible and measurements obtained after transplant reflect lung function of the new 
non-CF transplanted lungs. The use of CF-specific percentiles also allows for subjects 
with CF of different ages to be compared to one another despite the decline in lung 
function seen in CF patients. This phenotype is being utilized as it was the phenotype that 
has been shown to be associated with ambient temperature and demonstrated 
heritability.28,44 In addition, the use of average lung function measures may underestimate 
lung function in CF patients as CF patients do experience intermittent decreases in lung 
function associated with respiratory infections; thus, an “average lung function” measure 
may not capture the true lung function of a subject with CF when well, and the best 
percentile in the most recent year of data was used to correspond to the most recent 
location for a subject. The available data that we had for replication from the CF Patient 
Registry did not include longitudinal measures of lung function. Lastly, a non-CF based 
percentile for lung function was used for the general population NHANES study 
population as described in Section 1.5. 
Infection Data: Two variables related to each specific infectious organism were 
collected, namely (1) whether an individual had positive cultures for an organism as a 
qualitative measure of infection, and (2) the age at which that organism was acquired as 
quantitative measure. Quantitative measures of the burden of infection, such as colony 
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counts or cumulative burden of disease, were not available. Subjects were considered to 
be positive for an organism if they had any respiratory cultures positive for that organism. 
Age of acquisition for an organism was defined as the date of the first positive culture 
following at least one prior negative culture (Twin-Sibling Study only).51 Thirteen CF 
respiratory pathogens including Staphylococcus aureus, Methicillin resistant S. aureus 
(MRSA), non-tuberculous mycobacteria (NTM), Aspergillus fumigatus, 
Stenotrophomonas maltophilia, Achromobacter xylosoxidans, Haemophilus influenzae, 
Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Pseudomonas 
aeruginosa, mucoid P. aeruginosa, and Burkholderia cepacia were analyzed.  
Section 1.4. Approach for Chapter 3 
To identify gene-environment interactions that explain the association between 
temperature and lung function in (a) known genetic modifiers of CF lung disease, and/or 
(b) known genetic modifiers of lung function previously identified in the general 
population.  
Introduction: With thousands of genetic variants within the human genome and an 
equally large number of potential environmental factors that may affect lung function, the 
risk of false discovery is high when seeking evidence of gene-environment interactions. 
To minimize this risk, Chapter 3 reduced uncertainty by testing only replicated genetic 
modifiers of lung function and the replicated environmental factor of ambient 
temperature. Genetic modifiers tested included both those operating in CF and also those 
operating on lung function in the general population. The five known CF genetic loci 
tested included two replicated loci (chromosomes 11p13 and 20q13.2) identified through 
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genome-wide association and linkage studies by the North American CF Modifier 
Consortium,52 and polymorphisms in the mannose binding lectin (MBL2) gene supported 
through meta-analysis,53 transforming growth factor beta-1 (TGFB1) supported through 
multiple studies,54-58 and interferon-related developmental regulator 1 (IFRD1) identified 
via genome-wide association and replicated in an independent population.59 The four 
known CF genetic loci tested were identified and replicated in large (n=7691 to 20,890) 
population-based genome-wide association studies of lung function (FEV1 and 
FEV1/FVC ratio) in the general population.
60-63 These genes associated with lung 
function include hedgehog interacting protein (HHIP), advanced glycosylation end 
product-specific receptor (AGER), C-terminal domain containing glutathione S-
transferase (GSTCD), and 5-hydroxytryptamine receptor 4 (HTR4). Together these 
analyses may provide information on why lung function is highly variable in CF. 
Genetic Data: Genotyping has been performed for a sample of the Twin-Sibling 
Study population using the Illumina 610-Quad Array®, 660W-Quad Array®, and the 
Omni5 Array® under stringent quality control. Two of the known CF genetic loci have 
been identified using this array, specifically SNPs rs12793173 and rs4811626. For the 
other three known CF loci, polymorphisms for a subset of the Twin-Sibling Study have 
been typed. These include codons 52, 54, and 57 in exon 1 (D, B, and C variant alleles, 
respectively) and promoter polymorphisms at positions -550 (H/L variant) and -221 (X/Y 
variant) for MBL2, -509 promoter site and codon 10 in TGFB1, and the rs7817 
polymorphism in IFRD1. The known genetic modifiers of lung function in general 
population examined included HHIP, AGER, GSTCD, and HTR4. Analysis of these 
modifiers was imputation-based as they have not been genotyped in the Twin-Sibling 
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Population. The correlation between observed and imputed alleles with a similar 660K 
platform is 0.93, suggesting that imputing a marker for 1000 subjects provides similar 
data to genotyping that marker for 930 subjects.64,65 Within the CF Twin-Sibling Study 
there were a total of 1660 geocoded individuals with lung function and data on at least 
one polymorphism.  
Section 1.5. Approach for Chapter 4 
To determine if temperature is associated with lung function in the U.S. general 
population.  
Introduction: Although at a least portion of the association between temperature 
and lung function (that mediated by P. aeruginosa) is specific to individuals with CF, it is 
conceivable that some of the mechanisms contributing to this association are independent 
of CF. Thus, a multivariate regression was performed to identify associations between 
temperature and lung function in the general population. 
Study Populations: NHANES: The National Health and Nutrition Examination 
Survey (NHANES) is an ongoing survey conducted by CDC. It was designed to provide 
national estimates of the health and nutritional status of the United States' civilian, non-
institutionalized population aged two months and older. Surveys are periodically 
conducted to assess a variety of health outcomes and obtain clinical data, and some of 
these surveys included lung function testing. The three NHANES surveys that collected 
lung function data were the NHANES III (1988-1994) survey, the 2007-2008 survey, and 
the 2009-2010 survey. Lung function from the 2011-2012 survey was not released until 
December 2014 after analysis had been completed for Chapter 4. The NHANES III 
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database contains 20,757 individuals with pulmonary function tests obtained between 
1988 and 1994 from 89 survey locations across the U. S. Of note the NHANES III 
population was used to generate one of the most widely used population norms used for 
comparison of patients in clinical practice in the U.S.46 The 2007-2008 and 2009-2010 
surveys contain 6319 and 7079 subjects with lung function data, respectively. 
Lung Function: The clinical standard FEV1 percentile based on the NHANES 
population was used,46 and the best lung function value recorded for a subject was used 
per clinical practice. 
Temperature Data: Mean annual ambient temperature was generated for each 
individual in a similar manner to Chapters 2 and 3 using residential zip code.  
Questionnaire Data: Questionnaire data were used to exclude individuals with 
active tobacco use or asthma to provide a representative “healthy” study population. 
Chronic obstructive pulmonary disease (COPD) was not specifically captured by these 




CHAPTER 2. RESPIRATORY PATHOGENS MEDIATE THE 
ASSOCIATION BETWEEN LUNG FUNCTION AND 
TEMPERATURE IN CYSTIC FIBROSIS 
Section 2.1. Abstract  
Introduction: Mean annual ambient temperature is a replicated environmental 
modifier of cystic fibrosis (CF) lung disease with warmer temperatures being associated 
with lower lung function. The mechanism of this relationship is not completely 
understood.  However, Pseudomonas aeruginosa, a pathogen that infects the lungs of CF 
individuals and decreases lung function, also has a higher prevalence in individuals living 
in warmer climates.   We therefore investigated the extent to which respiratory pathogens 
mediated the association between temperature and lung function.  
Methods: Thirteen respiratory pathogens common in CF were assessed in 
multistep fashion using clustered linear and logistic regression to determine if any 
mediated the association between temperature and lung function. Analysis was performed 
in the CF Twin-Sibling Study (n=1730; primary population); key findings were then 
evaluated in the U.S. CF Foundation Data Registry (n=15,174; replication population).  
Results: In the primary population, three respiratory pathogens (Pseudomonas 
aeruginosa, mucoid P. aeruginosa, and methicillin-resistant Staphylococcus aureus) 
mediated the association between temperature and lung function. P. aeruginosa 
accounted for 19% of the association (p=0.003), mucoid P. aeruginosa for 31% 
(p=0.001), and MRSA for 13% (p=0.023).  The same three pathogens mediated 




Conclusions: We found that three important respiratory pathogens in CF mediated 
the association between lower lung function and warmer temperatures. These findings 
have implications for understanding regional variations in clinical outcomes, and 
interpreting results of epidemiologic studies and clinical trials that encompass regions 
with different ambient temperatures. 
Section 2.2. Introduction 
Cystic fibrosis (CF) is a life-limiting autosomal recessive disorder caused by 
mutations in the CFTR gene. Progressive obstructive lung disease and recurrent 
respiratory infections account for the majority of morbidity and mortality associated with 
CF. Although over 2000 variants within the CFTR gene have been described,66 
individuals with identical mutations who are the same age can have dramatically different 
severity of lung disease.3,4,67 Family-based studies suggest that half of this variation is 
attributable to genetic modifiers other than CFTR and half of this variation is due to 
environmental and/or stochastic (random) factors.29,30 Even though CFTR-specific 
mutation therapies are now clinically available, these new drugs are extremely 
expensive.68,69 Thus, it still remains important to identify specific environmental factors 
that ameliorate or exacerbate lung disease.  
The majority of previous studies examining the role of environmental factors that 
impact CF lung disease have focused on micro-environmental factors, or those specific to 
a particular patient or household. Examples of micro-environmental factors demonstrated 
to impact CF lung disease include secondhand smoke exposure,33-37 household 
income,39,70,71 maternal education,39 and health insurance status.39-42,44 Research on the 
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effects of macro-environmental factors, that is factors that simultaneously affect groups 
of patients by geographic area, has been more limited with the exception of air 
pollution.38  
We previously described an association between climate, specifically mean 
annual ambient temperature, on lung function in CF where warmer temperature were 
associated with lower lung function among 3 independent populations of individuals with 
CF in the continental United States and Australia.44 Our analyses also suggested that a 
portion of this association (6-22%) was mediated by a higher prevalence of the common 
CF respiratory pathogen Pseudomonas aeruginosa in warmer climates. Pseudomonas 
aeruginosa was also acquired earlier in warmer regions in retrospectively collected data 
from the United States and in prospectively collected data from Australia. Subsequently, 
geographic trends with the first acquisition/prevalence of P. aeruginosa were observed in 
other CF populations,72 including trends towards earlier acquisition and higher 
prevalence in the Southern states of the U.S.73,74  Given that P. aeruginosa could have 
accounted for a fraction of the association between lung function and ambient 
temperature, we sought to determine if any other common CF respiratory pathogens 










Section 2.3. Methods 
Ethics Statement and Recruitment: Written informed consent was obtained from 
participants (or their parents/legal guardians) enrolled in the CF Twin-Sibling Study (PI: 
G.R. Cutting). This study, including the CF Foundation Data Registry data downloads, 
was approved by the Johns Hopkins University Institutional Review Board. Primary 
Population: U.S. CF Twin and Sibling Study (CFTSS): Participants were recruited from 
CF centers based on having a twin or sibling also with CF (n=2086 in 1018 families).28 
Longitudinal data with multiple assessment timepoints were collected between 10/27/00 
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and 3/31/13 with data supplementation from the U.S. CF Foundation Data Registry 
through 12/31/11. Replication Population: U.S. CF Foundation Patient Registry 
(CFFDR): Anonymized cross-sectional data from the calendar year 2007 was provided 
(n=24,799). Participants were excluded if lung function, respiratory culture, or residential 
postal/zip code data were unavailable or they were living outside of the continental 
United States, or if self-reported to be actively smoking. CFTSS participants that were 
known to be enrolled in the CFF Patient Registry (n=1435) were excluded from the CFF 
sample.  
Exposure (Temperature) Variable: U.S. participants were mapped to the center of 
their most recent known residential zip code (finest resolution available) to derive 
measures for mean annual ambient temperature as this measure of temperature was 
previously found to be associated with lung function. Source data for mapping was 1981-
2010 mean annual ambient temperatures (The Climate Source; Corvallis, OR; 400 meter 
resolution). 
Outcome (Lung Function) Variable: Raw FEV1 (liters) measurements were 
converted into CF-specific percentiles excluding measurements obtained before 6 years 
of age and after lung transplantation.50 Lung function was defined as the best percentile 
in the most recent year of data.  
Potential Mediation (Respiratory Pathogen) Variable: Using all available 
respiratory culture data, participants were considered to be positive for a common CF 
respiratory pathogen (Achromobacter xylosoxidans, Aspergillus spp., Burkholderia 
cepacia complex, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, 
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non-tuberculous Mycobacteria spp., Pseudomonas aeruginosa, mucoid P. aeruginosa, 
Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus, Stenotrophomonas 
maltophilia, and/or Streptococcus pneumoniae) if they had any cultures positive for that 
pathogen. Data on culture source were not available for this study, but typically most 
clinical CF cultures were obtained via throat swab or expectorated sputum. 
Data Analysis: CFTSS participants served as the primary population and CFFDR 
as the replication population as the CFTSS participants were better characterized and had 
longitudinal data. Regressions clustered by family (CFTSS) or by CF care center 
(CFFDR), chi square, and student’s t-tests were performed using Stata 11 (StataCorp LP; 
College Station, TX). To establish whether the presence of individual respiratory 
pathogens (mediation variable) mediate the association between ambient temperature 
(exposure variable) and lung function (outcome variable), a standardized multistep 
process was utilized (See Figure 2.1 for schematic).48 The initial step of establishing the 
relationship between exposure and outcome was previously demonstrated in both the 
primary and replication populations.44 
The first step for this study was to determine whether mediation variables were 
associated with exposure through Generalized Estimating Equations (clustered 
regression) with a specific pathogen as the dependent variable, temperature as the 
independent variable, and adjustment for age. Using only mediation variables that were 
associated with exposure, the second step was to determine whether the mediation 
variables were associated with outcome through clustered linear regression with lung 
function as the dependent variable, a specific pathogen as an independent variable, and 
adjusted for age. Using only mediation variables that were independently associated with 
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exposure and outcome, the third step was to determine whether the mediation variables 
altered the relationship between the exposure and outcome variables through clustered 
linear regression with lung function as the dependent variable, a specific pathogen and 
temperature as independent variables; these regressions were also adjusted for age at the 
time of lung function and health insurance status based on previously published models.44  
We conducted these analyses separately in the primary and replication populations. 
The effect of mediation by infection on lung function was estimated by dividing 
the difference of regression coefficients of temperature adjusted and unadjusted for the 
mediator by coefficient of temperature unadjusted for the mediator.48,49 Confidence 
intervals for mediation were derived using the mediation package in STATA with 
clustered standard errors.75 P values for mediation were derived via the Sobel test.76,77 
Section 2.4. Results 
Demographics: The primary population for this study consisted of 1730 
participants from the CF Twin-Sibling Study (CFTSS)(n=2086) and the replication 
population for this study consisted of 15,174 participants from the U.S. CF Foundation 
Data Registry (CFFPR)(n=24,799) after exclusions. Comparisons of included vs. 




Table 2.1. Primary Study Population (CF Twin-Sibling Study) Included and Excluded 
Participants 
































(n = 2083) 
9.7% 
(n = 1729) 
8.2% 
(n = 354) 
0.39 
Age at Diagnosis 
(years) 
2.2 ± 5.3 
[0, 52] 
(n = 2084) 
2.3 ± 5.4 
[0, 52] 
 
1.6 ± 4.3 
[0, 33] 






(n = 2078) 
48.6% 
(n = 1728) 
45.4% 












Age at Last 
Respiratory Culture  
(years) 
18.1 ± 10.3 
[0, 67.0] 
(n = 2056) 
19.6 ± 9.7 
[5.3, 67.0] 
10.4 ± 9.6 
[0, 47.4] 
(n = 326) 
<0.001 
Age at FEV1 
Measurement 
(years) 
18.9 ± 9.6 
[6, 63.9] 
(n = 1894) 
19.0 ± 9.6 
[6, 63.9] 
18.2 ± 9.5 
[6, 48.4] 




69.2 ± 27.2 
[0, 100] 
(n = 1894) 
69.5 ± 26.9 
[0, 100] 
66.9 ± 30.5 
[0, 100] 








s Mean Annual Ambient 
Temperature  
(°F) 
54.3 ± 7.1 
[38.5, 76.5] 
(n = 1901) 
54.3 ± 7.1 
[38.5, 76.5] 
54.3 ± 7.1 
[42.6, 72.5] 





(n = 1933) 
31.9% 
35.0% 






Table 2.2. Replication Study Population (CF Foundation Data Registry) Included and 
Excluded Participants 





Data Registry  


























(n = 24,721) 
11.2% 
(n = 15,147) 
13.6% 
(n = 9574) 
<0.001 
Age at Diagnosis 
(years) 
3.5 ± 7.9 
[0, 78.5] 
3.8 ± 8.2 
[0, 73.7] 







(n = 22,248) 
49.8% 
(n = 13,644) 
47.7% 












Age at Last 
Respiratory Culture  
(years) 
17.7 ± 12.2 
[0, 74.2] 
(n = 22,801) 
20.7 ± 11.4 
[5.7, 74.2] 
11.7 ± 11.6 
[0.1, 73.3] 
(n = 7627) 
<0.001 
Age at FEV1 
Measurement 
(years) 
20.8 ± 11.5 
[6.0, 79.3] 
(n = 19,252) 
20.5 ± 11.4 
[6.0, 74.0] 
22.1 ± 11.8 
[6.0, 79.3] 




65.9 ± 26.3 
[0, 100] 
(n = 19,252) 
65.3 ± 26.4 
[0, 100] 
67.8 ± 25.9 
[0, 100] 













55.3 ± 7.7 
[32.2, 77.5] 
(n = 22,940) 
55.3 ± 7.8 
[34.3, 77.5] 
55.2 ± 7.6 
[32.2, 76.3] 





(n = 23,697) 
40.5% 
44.5% 
(n = 8523) 
<0.001 
 
In both populations, excluded participants had an earlier age of diagnosis and 
younger age at last respiratory culture. In the primary CFTSS population, excluded 
participants were also more likely to be male, and in the replication CFFDR population, 
excluded participants were more likely to be non-white, older at the measurement of lung 
function, have a higher CF-specific FEV1, and less likely to be homozygous for the most 
common CFTR mutation (F508del).  
There were also significant differences between the primary CFTSS and the 
replication CFFDR populations (Table 2.3), but owing to the large sample size of the 
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CFF population (n=15,174) and the magnitude of the differences, most differences were 
not clinically relevant.78  Still, a few differences were notable.   
Table 2.3. Primary and Replication Study Population Demographics 






(n = 1730) 
 
CF Foundation Data 
Registry 
(Replication) 


















(n = 1729) 
11.2% 
(n = 15,147) 
0.048 
Age at Diagnosis 
(years) 
2.3 ± 5.4 
[0, 52] 







(n = 1728) 
49.8% 












Age at Last 
Respiratory Culture  
(years) 
19.6 ± 9.7 
[5.3, 67.0] 
20.7 ± 11.4 
[5.7, 74.2] 
<0.001 
Age at FEV1 
Measurement 
(years) 
19.0 ± 9.6 
[6, 63.9] 





69.5 ± 26.9 
[0, 100] 









s Mean Annual 
Ambient Temperature  
(°F) 
54.3 ± 7.1 
[38.5, 76.5] 





31.9% 40.5% <0.001 
 
The primary CFTSS population had a younger age of diagnosis (2.3 vs. 3.8 years) 
and a higher CF-specific FEV1 measurements (69.5 vs. 65.3) than the replication CFFDR 
population. Individuals in the primary CFTSS population were less likely to have public 
health insurance (31.9 vs. 40.5%) than the replication CFFDR population. Some of these 
differences reflect the recruitment criteria for the CFTSS, namely having 2 living siblings 
or twins with CF, which resulted in study population that was younger and healthier than 
the general CF population,28  as well as earlier diagnosis for at least the younger sibling 
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owing to familial knowledge. There were no significant differences in the gender 
composition or frequency of F508del homozygotes between the two populations. 
The percentage of participants who had a culture with a specific respiratory 
pathogen ever is described in Table 2.4. For the primary CFTSS population, the 
percentages ranged from a low frequency of 8.6% for non-tuberculous mycobacteria to a 
high frequency of 98.0% for S. aureus. For the replication CFFDR population, the 
percentages ranged from 1.3% for E. coli and K. pneumoniae to 60.4% for P. aeruginosa. 
The prevalence frequencies for any given organism were higher in the CFTSS population 
compared to the CFFDR population. This pattern of findings likely reflects differences in 
study design; the CFTSS population incorporated longitudinal data with each subject 
having 16.2±7.1 years [Range: 0.4, 48.6] of respiratory culture data, whereas the CFFDR 




Table 2.4. Prevalence of Respiratory Pathogens in the Primary and Replication Study 
Populations 
Mean ± S.D. 
[Range in years] 
 





(%; n = 1730 
unless otherwise 
noted) 





Positive on any 
Respiratory 
Culture:  
CF Foundation  
(%; n = 15,174) 
Achromobacter xylosoxidans 
22.9 
13.7 ± 9.2 
[0.1, 62.9] 




14.1 ± 8.5 
[0.1, 56.9] 
(n = 835) 
16.4 
Burkholderia cepacia Complex 
8.8 
14.3 ± 8.3 
[0.7, 50.4] 




(n = 1258) 
3.8 ± 7.5 
[0.0, 57.2] 




6.8 ± 7.3 
[0.0, 55.0] 




5.9 ± 10.4 
[0.0, 61.3] 
(n = 147) 
1.3 
Non-tuberculous Mycobacteria spp. 
8.6 
19.6 ± 8.9 
[4.9, 49.7] 




6.8 ± 6.8 
[0.0, 53.8] 
(n = 1286) 
60.4 
Mucoid Pseudomonas aeruginosa 
62.7 
11.7 ± 8.4 
[0.2, 53.8] 




6.2 ± 7.2 
[0.0, 54.6] 




13.3 ± 8.9 
[0.0, 58.9] 




11.8 ± 9.0 
[0.0, 60.2] 




(n = 1258) 
7.8 ± 7.6 
[0.0, 44.9] 






Mediation STEP 1: Determining whether the mediation variable is associated with 
exposure: As previously mentioned, having previously established the association 
between temperature and lung function, we used a three step process to establish whether 
a specific infectious pathogen mediated the association between temperature and lung 
function (Figure 2.2).  
To assess whether annual ambient temperature was associated with specific 
respiratory pathogens, logistic regression was conducted in the primary CFTSS 
population for each pathogen. Clustering by family (adjusted estimates of variance) was 
performed as the presence of an organism for a subject may be influenced by his/her 
sibling/twin’s potential colonization with specific respiratory pathogens (Table 2.5). Of 
the 13 pathogens assessed, seven were associated with annual ambient temperature in the 
primary population, namely A. xylosidans, H. influenzae, K. pneumoniae, non-
tuberculous mycobacteria, P. aeruginosa, mucoid P. aeruginosa, and MRSA. Of these 7 
pathogens, only five were associated with temperature in the CFFDR replication 
population, namely H. influenzae, non-tuberculous mycobacteria, P. aeruginosa, mucoid 
P. aeruginosa, and MRSA.  Of note, there was a higher odds ratio for the presence of a 
pathogen associated with a warmer mean annual ambient temperature for these 





Table 2.5. Mediation STEP 1: Testing for the Association of Exposure Variable 






CF Twin-Sibling Study  
(Primary; n = 1730 unless otherwise 
specified) 
CF Foundation Data Registry  
(Replication; n = 15,174) 
Model p Value Temperature 
Odds Ratio2 
(per 10°F) 








































































































1All logistic regressions were clustered by family for the primary population and CF center for the replication 
population and adjusted for age at the time of the last respiratory culture in years. Regressions for the replication 
population were only performed for a respiratory pathogen if the pathogen was associated with temperature in the 
primary population.  
2Temperatures odds ratios represents the adjusted odds ratio that an individual has a positive culture for the specified 
respiratory pathogen for a 10°F increase in mean annual ambient temperature. I.e., there is a 1.27 increased odds of 
having a positive culture for A. xylosoxidans in the primary population for every 10°F increase in the mean annual 
ambient temperature. 
3Temperature odds ratios were not calculated for the replication population if the odds ratio for the primary population 




Figure 2.2. Graphical Depiction of Mediation Results 
 
Mediation STEP 2: Determining whether the mediation variable is associated with 
outcome: To assess whether specific respiratory pathogens were associated with lung 
function, clustered linear regression was conducted in the primary CFTSS population for 
the pathogens identified in Step 1 (Table 2.6). Of the 5 pathogens assessed, only 3 were 
associated with lung function (CF-specific FEV1) in the primary population, namely P. 
aeruginosa, mucoid P. aeruginosa, and MRSA. All three of these pathogens were also 
associated with lung function in the CFFDR replication population.  Each of these three 




Table 2.6. Mediation STEP 2: Testing for the Association of Potential Mediation 






CF Twin-Sibling Study  
(Primary; n = 1730) 
CF Foundation Data Registry  
(Replication; n = 15,174) 



















































1All logistic regressions were clustered by family for the primary population and CF center for the replication 
population and adjusted for age at the time of pulmonary function testing. Regressions for the primary population were 
only performed for a respiratory pathogen if the pathogen was associated with temperature in the replication population 
(Table 2.5). Regressions for the replication population were only performed for a respiratory pathogen if the pathogen 
was associated with lung function in the primary population.  
2Change in lung function coefficients represent the change in CF-specific FEV1 percentile that an individual with a 
positive culture for the specified respiratory pathogen has compared to an individual with negative cultures for that 
pathogen. I.e., the CF-specific FEV1 percentile is 14.8 percentile points lower on average in the primary population 
with at least one positive respiratory culture for P. aeruginosa. 
3Change in lung function co-efficients were not calculated for the replication population if the change for the primary 
population was non-significant (p>0.05). 
 
Mediation STEP 3: Determining whether the mediation variable is associated with 
outcome: To assess whether specific infectious organisms mediate the association 
between ambient temperature and lung function, we compared the effect of temperature 
on lung function in a base model without a respiratory pathogen to a mediation model 
which included one of the 3 respiratory pathogens identified in Step 2 (Table 2.7). All 3 
of the organisms identified in Step 2 partially mediated the association between 
temperature and lung function in both the primary and the replication populations. In the 
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primary CFTSS population, P. aeruginosa was found to account for 19% of the 
association (p=0.003; 95% C.I.: 10%, 79%) between temperature and lung function, 
mucoid P. aeruginosa was found to account for 31% (p=0.001; 95% C.I.: 16%, 100%), 
and MRSA for 13% (p=0.023; 95% C.I.: 7%, 60%). The degree of mediation observed in 
the replication CFFDR population was lower overall, with P. aeruginosa accounting for 
7% of the association (p<0.001; 95% C.I.: 6%, 11%) between temperature and lung 
function, mucoid P. aeruginosa accounting for 7% (p=0.002; 95% C.I.: 5%, 10%), and 
MRSA for 4% (p=0.002; 95% C.I.: 3%, 5%). We also assessed the effect of all three of 
these organisms simultaneously in both the CFTSS and CFFDR populations by placing 
all 3 organisms into the base model (adjusted for insurance status and age). The inclusion 
of all 3 organisms in the model suggested that these infectious organisms account for 
43% of the association between temperature and lung function in the primary CFTSS 




Table 2.7. Mediation STEP 3: Testing whether the Mediation Variable (Respiratory 
Pathogen) Mediates the Association between the Exposure Variable (Temperature) and 





CF Twin-Sibling Study  
(Primary; n = 1730) 
CF Foundation Data Registry  










































































































































1All logistic regressions were clustered by family for the primary population and CF center for the replication 
population and adjusted for age at the time of pulmonary function testing and health insurance status. Regressions for 
the primary population were only performed for a respiratory pathogen if the pathogen was associated with lung 
function in the replication population (Table 2.6). Change in lung function coefficients represent the change in CF-
specific FEV1 percentile for a 10°F increase in mean annual ambient temperature as well as a change in an individual 
with a positive culture for the specified respiratory pathogen has compared to an individual with negative cultures for 
that pathogen.  
2Percent mediation is derived by dividing the temperature coefficient from a model with a respiratory pathogen by the 
temperature coefficient from the base model, then subtracting that from 1. Confidence intervals and Sobel test p-values 
for mediation were obtained as described in the Methods and are not available for models with more than one mediator 
(i.e., more than one infectious organism).  
 
Section 2.5. Discussion 
A number of human pathogens are affected by climate, most notably those with 
arthropod vectors, but also water- and food-borne pathogens.45 Our study suggests that 
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pulmonary bacterial infections or colonization are associated with climatic factors in 
individuals with a chronic respiratory disease.44 We previously reported an association 
between mean annual ambient temperature and lung function in individuals with CF.  
Among 13 CF respiratory pathogens, we found that P. aeruginosa (all strains as well as 
mucoid only) and MRSA infection mediated the association between lung function and 
ambient temperature in two independent populations of individuals with CF.  This study 
extends our previous observation44 that a higher prevalence of P. aeruginosa is associated 
with warmer ambient temperature, and indicates that climactic factors may explain the 
higher rates of P. aeruginosa and MRSA lung infection in CF noted in Southern regions 
of the United States.74  
The factors behind the geographic distribution of these respiratory pathogens in 
CF are not clear. Possibilities include factors that favor acquisition or colonization of 
individuals with CF in warmer climates, a geographic distribution that mirrors that of the 
general population, and/or distribution by chance alone. Although P. aeruginosa is not a 
common pathogen in the general population, MRSA is. Limited data on the proportion of 
MRSA isolates among all S. aureus isolates suggests that there may be geographical 
trends in the distribution of the proportion of MRSA isolates from S. aureus isolates in 
the United States and Europe (Figures 2.3 and 2.4). Alternatively, warmer temperatures 
may favor colonization of individuals with CF with respiratory pathogens. For example, 
in vitro studies of biofilm resistance of P. aeruginosa and S. aureus can increase with 
increases in incubation temperature under the right circumstances.79,80 In addition, the 




Figure 2.3. Proportion of MRSA from S. aureus isolates in the general population by 
region in the United States. Map and Data are from The Center of Disease Dynamics, 







Figure 2.4. Proportion of MRSA from S. aureus isolates in the general population by 
country in Europe. Map and Data are from the European Centers for Disease Prevention 







We also found that the portion of the association between temperature and lung 
function that was mediated by these three pathogens varied by study population, with 
43% of the association accounted for by these organisms in the primary CFTSS 
population, but only 12% in the CFFDR population. The presence of respiratory 
pathogens was assessed through longitudinal data in the CFTSS population as opposed to 
cross-sectional data in the CFFDR population; these longitudinal data may provide more 
accurate information regarding infection status. Alternatively, the CFTSS had higher lung 
function and was younger than the CFFDR population, so it is possible that the presence 
of these pathogens had a more significant impact in absolute changes in lung function in 
this population.  
Our study has several strengths, including a well characterized primary population 
with longitudinal data. Our replication population includes the largest available database 
in term of numbers of participants with CF. Lung function testing in patients with CF is 
generally robust with multiple tests performed annually with routine clinical care. Our 
study also has several limitations, most notably the possibility of unmeasured 
confounders. For example, P. aeruginosa has been characterized as a highly diverse 
species,82 and geographic variation in MRSA strains has been documented.83  Thus it is 
possible that more virulent strains are geographically distributed in warmer climates by 
chance alone, and we did not account for strain differences. Likewise, the presence of 
non-tuberculous mycobacteria in CF respiratory cultures has been associated with 
unmeasured factor of vapor pressure, but not ambient temperature.84 Additionally, our 
model assumed that the mediation variables of infection act upon the outcome variable of 
lung function, whereas it is also possible that more severe lung disease could lead to an 
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increased propensity for infections. It is also possible that individuals with CF may have 
polymorphisms in modifier genes affecting infection acquisition/colonization that are 
geographically distributed owing to founder effects or immigration patterns. Our study 
was also subject to misclassification bias by geographic location as participants move 
over the course of their lifetimes. Still, 79.5% of the CFTSS participants and 77.6% of 
the CFFDR participants live within the state in which they were born with another 8% 
(CFTSS) and 7.3% (CFF) living within an adjacent state. Also, our respiratory culture 
data were obtained from clinical specimens largely obtained through sputum samples and 
throat swabs; the latter, in particular, may not accurately represent lower airway flora.18 
However, poor quality of culture data would likely bias our results to the null, rather than 
leading to positive associations.  Additionally, although we ascribed observed results to 
partial mediation it is possible that unmeasured confounders exist or that collider 
stratification bias was present. Lastly, our use of retrospective culture data may under- or 
overestimate the prevalence of respiratory pathogens depending on reporting biases by 
CF care centers who may not report all culture data to the CF Foundation.  
Our results imply that where patients live may impact outcomes, in so much as 
patients living in warmer climates may acquire P. aeruginosa, mucoid P. aeruginosa, or 
MRSA at earlier ages and/or it may be more difficult to eradicate or treat these 
respiratory pathogens in warmer climates. This would suggest that surveillance via 
respiratory cultures may need to be more frequent, or eradication and prevention may 
need to be more aggressive in clinics located in warmer climates.  The U.S. CF 
Foundation also compares CF care centers’ clinical outcomes (e.g., lung function). 
Accordingly, comparisons of centers may need to be weighted based on geographic 
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location as there may be factors dictating respiratory pathogen prevalence and lung 
function that are macro-environmental factors outside of their control.  
In addition, our results also may have implications for clinical studies that are 
conducted across a diverse geographic area, as results may need to be adjusted for 
climatic variation. Also, we note that climate change may affect the geographic 
distribution of specific infectious diseases.85 Given our observations that warmer 
temperatures were associated with several respiratory pathogens, it is possible that global 
warming may lead to a higher prevalence of specific pathogens among individuals with 
CF. Lastly, while CF patients may view warmer climates as more healthy, it is quite 
possible that living in warmer climates might lead to worse outcomes than living in 
colder climates. 
In conclusion, the prevalence of three important common respiratory pathogens in 
CF appeared to mediate the association between lower lung function and warmer 
temperatures. These findings have implications for understanding regional variations in 
clinical outcomes, and results of epidemiologic studies and clinical trials which 




CHAPTER 3. GENE MODIFIER TEMPERATURE INTERACTIONS 
IN CYSTIC FIBROSIS 
 
Section 3.1. Abstract 
Introduction: Patients with cystic fibrosis (CF) with identical mutations in the 
disease-causing gene can have drastically different lung function. Twin studies in CF 
have suggested that approximately 50% of the variation seen in CF lung disease is related 
to modifier genes and 50% is due to environmental factors. One replicated environmental 
modifier of CF lung function is mean annual ambient temperature whereby warmer 
temperatures are associated with lower lung function in CF, but the mechanism is 
unknown. We sought to test for genetic factors that modify the association of temperature 
with lung function (gene-environment interactions) that might account for this 
association.  
Methods: Using the residential postal code of participants in the CF Twin-Sibling 
Study (n=2086), these individuals were geocoded with a mean annual ambient 
temperature. Multivariate regression was used to test for gene-temperature interactions 
with 10 known gene modifiers of lung function in CF and 8 known gene modifiers of 
lung function among the general population, separately. 
Results: After Bonferroni correction for 11 independent tests, no significant gene-
environment interactions were identified to be associated with lung function (FEV1) in 




Conclusions: Although we did not identify any gene-environment interactions in 
our study, it is still remains important to identify gene-environment interactions in CF as 
well as elucidate the relationship between temperature and lung function in CF to identify 
susceptible individuals who could benefit from specific interventions to improve 
longevity. 
Section 3.2. Introduction 
Cystic fibrosis (CF) is one of the most common autosomal recessive disorders in 
the United States. The majority of morbidity and mortality associated with CF is due 
recurrent respiratory infections leading to decline in pulmonary function. Although the 
gene responsible for CF, CFTR, was identified in 1989,1 and over 1900 genetic variants 
have been described to date,66 many of the phenotypic manifestations of CF do not 
correlate with specific mutations.86 Most significantly, patients with identical CFTR 
mutations often have drastically different lung function.2-4 More recent twin and sibling 
studies in CF have suggested that approximately 50% of the variation seen in CF lung 
disease is related to modifier genes, and 50% is due to common/unique environmental 
factors.29,30 Understanding the sources of variation in CF lung disease is crucial in 
ameliorating its burden.  
Although several genetic modifiers have been identified through genome-wide 
studies and candidate approaches, the identified loci may not explain the variation seen in 
CF lung function. A recent GWAS study’s identified loci only accounted for 4-46% of 
the variation in lung function.52 Likewise, although a number of environmental factors 
have been associated with variation in CF lung function, based on a multi-factor study,44 
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it is likely that the currently identified environmental factors also only account for a small 
portion of variation. One previously identified environmental modifier of CF lung 
function is mean annual ambient temperature whereby warmer temperatures are 
associated with lower lung function in CF, which we previously described in 3 
independent populations of patients with CF.44  
Unaccounted for sources of variation may be unstudied genetic or environmental 
factors, but may also include gene-environment interactions. With thousands of genetic 
variants within the human genome and an equally large number of potential 
environmental factors that may affect lung function, the risk of false discovery is high 
when seeking evidence of gene-environment interactions. To minimize this risk, our 
study reduces uncertainty by testing only replicated genetic modifiers of lung function 
and the replicated environmental factor of ambient temperature. 
We hypothesize the association of temperature and lung function in CF differs by 
genotype in selected modifier genes. In this study we tested for gene-environment 
interactions in several replicated loci of CF lung disease including two loci 
(chromosomes 11p13 and 20q13.2) identified through genome-wide association and 
linkage studies by the North American CF Modifier Consortium,52 and polymorphisms in 
the mannose binding lectin (MBL2) gene supported through meta-analysis,53 in the 
transforming growth factor beta-1 (TGFB1) gene supported through multiple studies,54-58 
and in interferon-related developmental regulator 1 (IFRD1) gene identified via genome-
wide association and replicated in an independent population.59 Within our CF study 
population we also tested for interactions in several modifiers of lung function replicated 
in the general population in large (n=7691 to 20,890) population-based genome-wide 
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association studies of lung function (FEV1 and FEV1/FVC ratio), including hedgehog 
interacting protein (HHIP), advanced glycosylation end product-specific receptor 
(AGER), C-terminal domain containing glutathione S-transferase (GSTCD), and 5-
hydroxytryptamine receptor 4 (HTR4).60-63 Together these analyses may provide 
information on why lung function is highly variable in CF.  The above analyses were 
carried out in the CF Twin-Sibling Study population as this represents the largest sample 
of CF subjects with genetic data recruited over a wide temperature range to date. 
Section 3.3. Methods 
Study Population: This study was approved by the Johns Hopkins University 
Institutional Review Board (NA_00035659, NA_00019677). Subjects were recruited 
from CF centers based on having a twin or sibling also with CF (Table 3.1: n=2086 in 
1018 families).28 Data were collected between 10/27/00 and 3/31/13 with data 
supplementation from the U.S. CF Foundation Patient Registry through 12/31/11. 
Subjects were excluded if lung function, residential postal/zip code data, health insurance 




Table 3.1. Study Population  
Mean ± S.D. Study Population 
(n = 1660) 
Excluded Subjects 
(n = 426) 
 
P value 
Sex (% male) 51.8% 56.6% 0.08 
Race (% any non-white) 7.9% 
(n = 1637) 
8.9% 
(n = 417) 
0.53 
Ethnicity (% Hispanic) 5.1% 
(n = 1659) 
5.9% 
(n = 424) 
0.56 
Age at Diagnosis (years) 
2.3 ± 5.5 
[0.0, 52.0] 
1.8 ± 4.3 
[0.0, 33.0] 
(n = 424) 
0.043 
CFTR genotype  
(% F508del homozygotes) 
48.7% 
45.7% 









69.5 ± 27.0 
[0, 100] 
 
67.7 ± 28.9 
[0, 100] 
(n = 234) 
0.36 
Age (years at the time of 
FEV1 measurement) 
19.2 ± 9.6 
[6.0, 63.9] 
 
16.9 ± 9.0 
[6.0, 48.4] 
(n = 234) 
0.001 








54.2 ± 7.0 
[38.5, 76.5] 
55.5 ± 7.6 
[42.6, 76.5] 
(n = 241) 
0.007 
 
Genetic Data: Genotyping has been previously performed for a sample of the 
Twin-Sibling Study population using the Illumina 610-Quad Array®, 660W-Quad 
Array®, and the Omni5 Array® under stringent quality control.52 Two of the known 
genetic modifiers of CF lung disease have been identified using these arrays, specifically 
SNPs rs12793173 and rs4811626.52 For the other three known CF loci, polymorphisms 
for a subset of the Twin-Sibling Study have been previously typed. These include codons 
52, 54, and 57 in exon 1 (D, B, and C variant alleles, respectively) and promoter 
polymorphisms at positions -550 (H/L variant) and -221 (X/Y variant) for MBL2, -509 
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promoter site and codon 10 in TGFB1, and the rs7817 polymorphism in IFRD1.33,59,87 
The known genetic modifiers of lung function in general population to be examined 
include HHIP, AGER, GSTCD, and HTR4.60-63 Actual genotype data was not available 
for all SNPs (Table 3.2), so imputation was performed using MaCH/Minimac software 
(http://www.sph.umich.edu/csg/abecasis/MACH/index.html).  Phase I, Version 3 
haplotype data from 1000 Genomes project (ftp://ftp-trace.ncbi.nih.gov/1000genomes 
/ftp/release/20110521/) was used as the reference. Samples were imputed separately by 
genotyping platform. Genotyped SNPs with a low minor allele frequency and low call 
rate were excluded prior to imputation. Imputed SNPs with a MaCH quality score 
r2<0.30 were excluded from the analysis. For the purposes of analyses, SNPs were coded 
in an additive manner (0=homozygous for the major allele, 1=heterozygous for the minor 
allele, 2=homozygous for the minor allele).  An additive model was selected as being 
more agnostic than dominant or recessive models. In addition, a composite variable was 
generated to estimate MBL “sufficiency” as previously described by our group.87 
Specifically, diplotypes of amino-acid substitutions associated with the minor alleles in 
codons 52, 54, and 57 (B,C, and D) and specific alleles at promoter site -221 may lead to 




Table 3.2. Imputation and Minor Allele Frequency  
























rs12793173 T/C 1594 2.8 22.11 16.99 <0.001 
Chromosome 
20 Locus 
rs4811626 C/T 1594 0.0 44.07 34.48 <0.001 








rs7096206 C/G 1619 31.0 20.40 19.55 0.44 
MBL2  
(codon 52) 
rs5030737 C/T 1619 28.4 6.69 2.72 <0.001 
MBL2  
(codon 54) 
rs1800450 G/A 1660 0.0 14.40 12.20 0.02 
MBL2  
(codon 57) 




rs1800469 C/T 1598 33.3 31.90 36.80 <0.001 
TGFB1  
(codon 10) 
rs1800470 T/C 1538 41.9 41.28 45.47 0.002 
HHIP (SNP 
1) 
rs12504628 T/C 1340 100.0 40.96 30.39 <0.001 
HHIP (SNP 
2) 
rs13147758 A/G 1340 100.0 40.56 28.85 <0.001 
HHIP (SNP 
3) 
rs1980057 C/T 1340 96.7 40.48 28.61 <0.001 
GSTCD 
(SNP 1) 
rs10516526 A/G 1594 2.8 6.12 3.17 <0.001 
GSTCD 
(SNP 2) 
rs11097901 C/T 1340 100.0 6.16 3.61 <0.001 
HTR (SNP 1) rs11168048 T/C 1340 96.7 41.94 43.01 0.45 
HTR (SNP 2) rs3995090 A/C 1594 2.8 41.98 44.37 0.08 
AGER rs2070600 G/A 1594 0.0 4.77 7.25 <0.001 
 
Environmental Data: U.S. subjects were mapped to the center of their most recent 
known residential zip code (finest resolution available) to derive measures for mean 
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annual ambient temperature (°F). Source data for mapping was 1981-2010 mean annual 
ambient temperatures (The Climate Source; Corvallis, OR; 400 meter resolution). 
Outcome Variables: Raw FEV1 (liters) measurements were converted into CF-
specific FEV1 percentiles excluding measurements obtained before 6 years of age and 
after lung transplantation.50 Lung function was defined as the best percentile in the most 
recent year of data. 
Data Analysis: Regressions clustered by family (CFTSS) to account for familial 
relationships, chi square tests, and student’s t-tests were performed using Stata 11 
(StataCorp LP; College Station, TX). The interaction between each SNP and temperature 
was assessed through clustered linear regression with specific SNPs and temperature (and 
an interactive term derived by multiplying them) as the independent variables and lung 
function as the dependent variable; these regressions were also adjusted for age at the 
time of lung function and health insurance status based on previously published models.44 
Although this is single hypothesis testing with relatively few genetic modifiers being 
tested for interactions, Bonferroni correction for multiple tests was performed to provide 
the most conservative estimates of association. 
Section 3.4. Results 
Demographics: A total of 2086 individuals have been consented into the CF Twin 
and Sibling Study, of which 1660 (79.6%) met study inclusion criteria. Included subjects 
were 51.8% male and 7.9% were self-reported as non-white (Table 3.1). In terms of 
CFTR genotype, 48.7% were homozygous for the most common allele F508del similar to 
the general CF population. The mean FEV1 specific percentile was 69.5±27.0, which is 
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higher than in the general CF reference population.50 Included subjects had an older age 
of diagnosis (2.3 years vs. 1.8 years; p=0.043) and older age at the time of pulmonary 
function testing (19.2 years vs. 16.9 years; p=0.001) than excluded subjects. Included 
subjects also were more likely to have pancreatic insufficiency (86.8% vs. 80.1%; 
p<0.001) and reside in slightly cooler climes on average (54.2 vs. 55.5°F; p=0.007) than 
excluded subjects. There were no differences in frequencies or means between included 
and excluded subjects in terms of sex, race/ethnicity, CFTR genotype, or CF-specific 
FEV1. 
SNP Data: Owing to the different sources of genotyping, the 18 SNPs of interest 
had differing frequencies for imputed data, ranging from some SNPs being fully imputed 
to others being completely genotyped (Table 3.2). The minor allele frequencies 
statistically differed from reported frequencies in dbSNP for all but 3 SNPs, the two in 
the HTR gene and the MBL2 -221 promoter site. For analysis, a composite variable for 
MBL2 sufficiency status was derived from 4 MBL2 SNPs (-221 promoter site, and 
codons 52, 54, and 57) with 247 subjects described as “insufficient” (15.3%) and 1372 
described as “sufficient” (84.7%). Although gene-environment interactions were tested 
for in 14 SNPs and the composite MBL2 status variable, it is recognized that these tests 
may not be independent tests owing to linkage within genes. In our study there were 5 
genes/loci of interest which contained 2 or more SNPs of interest; correlation between 
these SNPs was assessed (Table 3.3). Conservatively, we assumed only SNPs with very 
high correlation would be considered dependent tests for statistical purposes, which 
would include the SNPs on the HHIP, GSTCD, and HTR genes. Thus, the subsequent 
interaction testing was Bonferroni corrected for performing 11 tests (i.e., one each for 
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HHIP, GSTCD, and HTR gene SNPs, one for the composite MBL2 variable, and one each 
for the remaining 7 SNPs). 














MBL2 (-550) 0.046 
(n=1619) 





- - - - 










- - - - 0.990 
(n=1340) 
- 
HTR (SNP1) - - - - - 0.987 
(n=1340) 
 
Gene-Environment Interactions: Clustered linear regressions were performed 
using each SNP as an independent variable and lung function as the dependent variable 
(Table 3.4). In univariate analysis, two SNPs were associated with lung function (TGFB1 
-509 promoter site and GSTCD SNP rs11097901). These SNPs were also associated with 
lung function in multivariate regression after adjustment for age at the time of lung 
function testing, mean annual ambient temperature, and insurance status. However, 
assuming a Bonferroni corrected p-value of 0.0045 (0.05/11 independent tests), none of 
these SNPs remained associated with lung function after correction for multiple tests. To 
test for interactions, an interaction term (temperature-SNP) was added to the multivariate 
regression models for each SNP. Although 1 SNP and its interaction term was associated 




Table 3.4. Linear Regressions for Change in Lung Function Percentile by SNP 
Coefficient 








Coefficient for SNP 
by Multivariate 
Regression3 










(p = 0.57) 
-0.81 
[-3.26, 1.64] 
(p = 0.52) 
1.25 
[-20.09, 22.59] 
(p = 0.91) 
-0.04 
[-0.43, 0.36] 





(p = 0.92) 
-0.37 
[-2.39, 1.64] 
(p = 0.72) 
-11.62 
[-27.50, 4.25] 
(p = 0.15) 
0.21 
[-0.09, 0.50] 
(p = 0.17) 
IFRD1 1594 0.04 
[-2.08, 2.17] 
(p = 0.97) 
-0.26 
[-2.32, 1.80] 
(p = 0.81) 
-22.45 
[-40.44, -4.46] 
(p = 0.015) 
0.41 
[0.07, 0.74] 





(p = 0.21) 
-1.58 
[-3.64, 0.49] 
(p = 0.14) 
-2.37 
[-20.82, 16.07] 
(p = 0.80) 
0.01 
[-0.32, 0.35] 






(p = 0.28) 
2.56 
[-1.11, 6.25] 
(p = 0.17) 
4.37 
[-25.06, 33.80] 
(p = 0.77) 
-0.03 
[-0.57, 0.51] 





(p = 0.006) 
-2.92 
[-5.04, -0.79] 
(p = 0.007) 
11.03 
[-5.97, 28.03] 
(p = 0.20) 
-0.26 
[-0.57, 0.05] 





(p = 0.06) 
-2.04 
[-4.12, 0.05] 
(p = 0.06) 
10.72 
[-6.75, 28.20] 
(p = 0.23) 
-0.24 
[-0.55, 0.08] 
(p = 0.15) 
HHIP (SNP 1) 1340 1.31 
[-1.02, 3.63] 
(p = 0.27) 
1.32 
[-0.97, 3.62] 
(p = 0.26) 
9.45 
[-7.69, 26.60] 
(p = 0.28) 
-0.15 
[-0.46, 0.16] 
(p = 0.34) 
HHIP (SNP 2) 1340 1.32 
[-0.96, 3.61] 
(p = 0.26) 
1.42 
[-0.83, 3.67] 
(p = 0.22) 
10.37 
[-6.61, 27.35] 
(p = 0.23) 
-0.16 
[-0.47, 0.14] 
(p = 0.29) 
HHIP (SNP 3) 1340 1.51 
[-0.77, 3.78] 
(p = 0.19) 
1.60 
[-0.64, 3.83] 
(p = 0.16) 
10.60 
[-6.33, 27.53] 
(p = 0.22) 
-0.17 
[-0.47, 0.14] 
(p = 0.29) 
GSTCD (SNP 1) 1594 3.04 
[-1.23, 7.32] 
(p = 0.16) 
2.79 
[-1.40, 6.97] 
(p = 0.19) 
-21.96 
[-57.11, 13.22] 
(p = 0.22) 
0.46 
[-0.20, 1.11] 
(p = 0.17) 
GSTCD (SNP 2) 1340 6.23 
[1.75, 10.71] 
(p = 0.007) 
5.74 
[1.25, 10.23] 
(p = 0.012) 
-25.98 
[-62.60, 10.64] 
(p = 0.16) 
0.58 
[-0.09, 1.26] 
(p = 0.09) 
HTR (SNP 1) 1340 0.13 
[-2.21, 2.46] 
(p = 0.92) 
0.17 
[-2.16, 2.51] 
(p = 0.89) 
-12.92 
[-31.44, 5.59] 
(p = 0.17) 
0.24 
[-0.09, 0.57] 
(p = 0.16) 
HTR (SNP 2) 1594 -0.14 
[-2.19, 1.92] 
(p = 0.90) 
0.04 
[-2.02, 2.11] 
(p = 0.97) 
-6.97 
[-23.05, 9.10] 
(p = 0.40) 
0.13 
[-0.16, 0.42] 
(p = 0.38) 
AGER 1594 -2.29 
[-7.54, 2.97] 
(p = 0.39) 
-2.46 
[-7.53, 2.62] 
(p = 0.34) 
-15.16 
[-61.19, 30.87] 
(p = 0.52) 
0.23 
[-0.61, 1.08] 
(p = 0.59) 
1Based on the data presented in Table 3.3, it is assumed that 11 independent tests are being performed, thus the Bonferroni corrected 
p-value is 0.05/11 or 0.0045. None of the SNP co-efficient or interaction term p values meet this threshold.  
2All regressions include lung function (FEV1) as the dependent variable and genotype for a SNP coded by the number of minor 
alleles as the independent variable, and are clustered by family. 
3Multivariate regression includes adjustment for age at the time of lung function measurement in years, mean annual ambient 
temperature in degrees Fahrenheit, and insurance status coded as 0 for private insurance and 1 for public insurance.  
4The interaction term is derived by multiplying the SNP variable and the value for temperature. 
5MBL Sufficiency Status is a composite variable with MBL sufficiency or insufficiency defined on the basis of MBL2 diplotypes 
incorporating data from MBL2 SNPs in the -221 promoter site, and codons 52, 54, and 57.  
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Section 3.5. Discussion 
Lung disease in cystic fibrosis is a complex phenotype, influenced by mutations 
in the disease-causing CFTR gene itself, polymorphisms or mutations in other modifier 
genes, and environmental/stochastic factors.29 We have previously described mean 
annual ambient temperature as an environmental factor associated with lung function in 
CF.44 Although a portion of this association is explained by the geographic distribution of 
common respiratory pathogens in CF, the remaining mechanism(s) are unknown. We 
hypothesized that the remaining unexplained portion of the association between 
temperature and CF lung function might be secondary to gene-environment interactions 
between temperature and known modifier loci/genes in CF. However, regression-based 
testing did not identify any significant gene-environment interactions for any of the 14 
tested SNPs or the composite MBL2 status variable. 
The findings may be truly negative as the association between temperature and 
lung function in CF may not be mediated through the tested genetic modifiers, but rather 
the association might be mediated by other untested modifier genes or other 
environmental factors. Alternatively, there is a relationship, but we are underpowered to 
detect gene-environment interactions with a study population of 1660 subjects with 
genotypes with a minor allele frequency of less than 20%. Assuming a modest main 
genetic effect of 2.0 percentile points per minor allele, a main environmental effect of 0.3 
percentile points per temperature degree based on previously published data, and a 
relatively robust gene-environment interaction effect of 0.5 percentile points (a decrease 
of an additional 0.5 percentile points of lung function per degree of temperature with an 
at-risk genotype), a post-hoc power calculation using Quanto88 suggests that we had 
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>80% power to detect interactions with SNPs with a minor allele frequency >0.2 and 
>60% power for SNPs with a minor allele frequency >0.1. It is also possible that our 
Bonferroni correction for multiple testing is too stringent.  
Perhaps the biggest study limitation was misclassification bias when assigned 
mean annual ambient temperatures. Although subjects may reside in multiple locations 
over a lifetime, lung function from the most recent year of data and each subject’s last 
known location were used to minimize this uncertainty. Furthermore, in a prior study we 
found that 79.5% of the CF Twin-Sibling Study subjects live within the state in which 
they were born with another 8% living within an adjacent state (n=1313).44 Other 
potential limitations include the use of imputed SNP data, although the correlation 
between observed and imputed alleles with a similar 660K platform is 0.93, suggesting 
that imputing a marker for 1000 subjects would provide similar data to genotyping that 
marker for 930 subjects.64,65 It is also possible that the association between temperature 
and lung function is mediated by one of the studied SNPs through a non-additive model, 
which was not employed in this study as we felt an additive model to be more agnostic 
than dominant or recessive models. 
Although we did not identify any gene-environment interactions in our study, we 
hope that our approach highlights the importance of testing for gene-environment 
interactions with both replicated genetic and environmental modifiers to minimize false 
positive findings. It is still remains important to identify gene-environment interactions in 
CF as well as elucidate the relationship between temperature and lung function in CF to 




CHAPTER 4. WARMER TEMPERATURES ARE ASSOCIATED 
WITH LOWER LUNG FUNCTION IN HEALTHY INDIVIDUALS 
Section 4.1. Abstract 
Background: Climate change may have many effects on human health, including 
lung function. Previous work has shown an association between warmer ambient 
temperature and lower lung function (FEV1) in individuals with cystic fibrosis. We 
hypothesized that a similar relationship may exist within the general population. 
Methods: Spirometry (FEV1) data from two National Health and Nutrition 
Examination Survey cohorts representative of the U.S. non-institutionalized population 
(NHANES III: 1988-94; NHANES continuous: 2007-10) were merged with mean 
ambient annual temperature data and associations were assessed for using survey-
weighted multivariate regression. 
Results: After adjusting for potential demographic confounding factors, warmer 
temperatures were associated with lower lung function in both the NHANES III 
population (p=0.016; n=10,628) and the NHANES 2007-2010 population (p=0.002; 
n=9024). The effect was modest in both populations with a 0.7%  and 1.0% predicted 
FEV1 decrease for every 10°F increase in mean annual ambient temperature in the 
NHANES III and NHANES 2007-2010 populations, respectively. 
Conclusions: Temperature influences lung function in the general population. 
While the influence may be modest in the general population, the effect size of the 
association may be greater in populations with respiratory disease, such as cystic fibrosis, 
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which may have ramifications for other obstructive respiratory disorders, such as asthma 
and COPD.  
Section 4.2. Introduction 
The primary function of the respiratory tract is gas exchange. A wide variety of 
tests have been developed to assess pulmonary function including spirometry which 
provides quantitative estimates of lung volumes and air flow obstruction. As spirometry 
is a commonly employed test in both primary care and subspecialty offices as a measure 
of lung disease (e.g., asthma, COPD, cystic fibrosis, pulmonary fibrosis, etc.), it is 
important to understand the factors that influence it. 
Studies of monozygous twins who share 100% of their genes and dizygous twins 
who share 50% of their genes have produced differing estimates of heritability with some 
studies demonstrating more limited genetic effects on lung function,89,90 and others 
suggesting that genetic factors may account for over half of the variation in lung 
function.91,92 Taken together these studies imply that lung function is complex trait with 
both genetic and environmental factors contributing to its variation. A number of 
environmental factors that impact lung function on an individual level have been 
described, such indoor combustion,93 environmental tobacco smoke,94 and proximity to 
traffic.95-97 Fewer environmental factors that impact lung function in large numbers of 
individuals simultaneously over a wider geographical area have been described, but 
include air pollution.96,98 Another large-scale geographic factor which may impact lung 
function, and respiratory health overall, is climate.  
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In the context of climate change, it is important to understand the role of 
temperature on disease.99 Ambient temperature has been demonstrated to be associated 
with the prevalence of both infectious and non-infectious diseases,45 particularly vector-
borne infectious diseases. The acute effects of temperature on respiratory diseases has 
been perhaps best studied in COPD with increased mortality and morbidity with both hot 
and cold temperature extremes.100 Acute temperature changes may also have an effect on 
respiratory symptoms in asthma.101,102 Potential long-term effects of ambient temperature 
on lung function are less well studied. However, we have previously demonstrated a 
novel association between lower lung function (FEV1) in individuals with cystic fibrosis 
and warmer annual ambient temperatures with replication in two national cystic fibrosis 
registries in the United States and Australia.44 
We hypothesize that mean annual ambient temperature is associated with 
variation in lung function in healthy individuals without cystic fibrosis or other lung 
diseases. To test this hypothesis, we assessed cross-sectional lung function (FEV1) in 
healthy non-smokers in the United States using two separate cohorts from the National 
Health and Nutrition Examination Survey (NHANES), which collected both geographic 
and spirometry data.  
Section 4.3. Methods 
Study Population: De-identified data were utilized from the National Health and 
Nutrition Examination Survey (NHANES) conducted by the National Center for Health 
Statistics (NCHS). NHANES is a series of surveys that collect questionnaire and medical 
testing data on a sample of the non-institutionalized U.S. population. All surveys where 
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spirometry was routinely performed were used, including the periods 1988-1994 
(NHANES III), 2007-2008, and 2009-2010. The NHANES 2007-2008 and 2009-2010 
data were combined for analysis as they utilize similar survey weights. The primary 
population was the NHANES III study population as a “representative” sample of the 
U.S. general population. The NHANES 2007-08 and 2009-10 data were used to replicate 
the analysis. To obtain a sample of participants in good respiratory health, participants 
were excluded if they had any mention of asthma or any reported active tobacco product 
use. Of note, specific questions for COPD were not asked of the study populations. 
Demographic Data: Raw data for sex, age, race/ethnicity, annual household 
income, and insurance status were all obtained from NHANES publically available 
datafiles. Any participant reporting any non-white race or Hispanic ethnicity was coded 
as non-white for the purposes of regression modeling. Participants who had insurance 
were coded as either having no insurance, public insurance, or private insurance with any 
mention of private insurance being coded as private for the purposes of regression 
modeling. 
Lung Function Data: Raw forced expiratory volume in 1 second (FEV1) in 
milliliters was converted to percent predicted using NHANES reference equations.46,103 
Participants without valid FEV1 data were excluded.  
Temperature Data: Temperature source data consisted of a 30 year average of 
temperature (1980-2010; The Climate Source, Inc.; Corvallis, OR) to minimize year-to-
year variation. Participants were geocoded for annual ambient temperature to the 
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population centroid of their last known residential postal zip code using ESRI ArcGIS 
(ESRI; Redlands, CA).44  
Statistical Analyses: Student’s t tests and chi-square tests were used to compare 
demographic factors between included and excluded participants. Linear regression was 
performed to determine if temperature was associated with lung function using separate 
models for the NHANES III data and the NHANES 2007-2010 data. The final models 
adjusted for demographic factors that were associated with lung function in univariate 
regression, including sex, race/ethnicity, age, the log value of household income, and 
insurance status if these factors were associated with lung function in univariate models. 
Although participants are selected to represent the U.S. population at all ages, NHANES 
routinely oversamples persons aged 60 years and older, African-Americans, and 
Hispanics, thus all regressions were survey weighted per recommended NHANES 
analytic practices.104 Random effects meta-analysis was used to provide a combined 
estimate of effect size from both NHANES datasets.105 All statistical analyses were 
conducted using STATA IC 11 (College Station, TX) at the NCHS RDC facility 
(Hyattsville, MD) owing to the use of restricted data (zip code). A p value of <0.05 was 
considered statistically significant. 
Section 4.4. Results 
Demographics: The NHANES III sample consisted of 25,733 participants over 6 
years of age who could have had spirometry measurements, of which 4446 did not have 
spirometry performed for administrative reasons or medical exclusions. We excluded an 
additional 6432 participants, including 1315 participants without zip codes that could not 
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be geocoded for mean annual ambient temperature, 727 participants with asthma, and 
4390 participants with active tobacco use, to yield a NHANES III study population of 
14,855 participants whose data were used for analyses. The NHANES 2007-2010 sample 
consisted of 17,244 participants over 6 years of age who could have had spirometry 
measurements, of which 4972 did not have spirometry performed for administrative 
reasons or medical exclusions. We excluded an additional 3248 participants, including 3 
participants without zip codes that could not be geocoded for mean annual ambient 
temperature, 1034 participants with asthma, and 2211 participants with active tobacco 
use, to yield a NHANES 2007-2010 study population of 9024 participants whose data 
were used for analyses.  
Survey weighted means for selected demographic variables, which account for 
NHANES oversampling of certain demographic groups, are reported in Table 4.1. 
Comparisons between excluded and included populations are reported in Table 4.2. The 
differences between the included and excluded populations largely related to the 
exclusion of participants with active tobacco use, which was more common among 
males, Blacks and Whites, older participants, and participants with lower reported 




Table 4.1. Survey Weighted Means for Study Populations 
Mean  
 
NHANES III Data NHANES 2007-2008 and 2009-2010 Data 
n = 14,855 n = 9024 













Age (years) 37.4 37.6 


















Temperature (°F) 57.2 56.7 
FEV1 (% Predicted) 98.6 99.0 
 
Table 4.2. Included and Excluded Populations 
Mean ± S.D. NHANES III Data NHANES 2007-2008 and 2009-2010 Data 
Included Participants 
(n = 14,855) 
Excluded 
Participants 
(n = 10,878) 
Included Participants 
(n = 9024) 
Excluded 
Participants 
(n = 8220) 






















Age (years) 37.1 ± 23.5 42.5 ± 24.2 35.1 ± 22.0 43.1 ± 23.6 
Income ($’000s) 25.4 ± 15.6 
 (n=13,526) 
23.3 ± 15.3 
 (n=9554) 
50.2 ± 32.1 
 (n=8668) 
40.3 ± 30.0 
 (n=7797) 
























Asthma (% yes) 0.0 8.5 0.0 18.4 
Tobacco Use (% 
yes) 
0.0 52.4 0.0 37.0 
Temperature 
(°F) 
60.1 ± 7.7 
59.5 ± 7.6 
(n=9943) 
58.3 ± 8.4 




99.4 ± 15.7 
92.7 ± 18.0 
(n=5845) 
100.0 ± 14.2 
93.1 ± 16.4 
 (n=3248) 
 
Potential Confounders: Survey-weighted univariate modeling of the association of 
lung function and various demographic factors was performed to identify potential 
confounding factors (Table 4.3). The two study populations demonstrated a similarity in 
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the effect of confounders such as race and age while higher reported incomes and private 
insurance were associated with higher lung function only in the NHANES III population, 
whereas female sex was associated with higher lung function only in the NHANES 2007-
2010 population. For the multivariate regression analyses that follow significant factors 
were included as covariates.  
Table 4.3. Survey Weighted Univariate Regressions 
Coefficient (change in 
FEV1 % predicted) 
[95% C.I.] 
NHANES III Data NHANES 2007-2008 and 2009-2010 
Data 
n = 14,672 Coefficient P value n = 9024 Coefficient P value 







































Relationship of Lung Function with Temperature: In survey weighted univariate 
modelling, higher temperatures were not associated with lower lung function in the 
NHANES III population (p=0.19) or the NHANES 2007-2010 population (p=0.17). In 
survey weighted multivariate regression incorporating the covariates identified through 
univariate (Table 4.4), higher temperatures were associated with lower lung function in 
both the NHANES III population (p=0.016) and the NHANES 2007-2010 population 
(p=0.002). The effect was modest in both populations with a 0.7  and 1.0 percentile point 
FEV1 decrease for every 10°F increase in mean annual ambient temperature in the 
NHANES III and NHANES 2007-2010 populations, respectively. Meta-analysis 
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incorporating both study results yielded an estimated effect size of 0.9 percentile point 
decrease for every 10°F increase (95% C.I.: 0.5%, 1.3%; p<0.001). 
Table 4.4. Survey Weighted Multivariate Regressions Adjusted for Potential 
Confounders for Study Population 
Coefficient (change in 
FEV1 % predicted) 
[95% C.I.] 
NHANES III Data NHANES 2007-2008 and 2009-2010 
Data 
n = 10,628 Coefficient P value n = 9024 Coefficient P value 
Sex (male=0; male=1) Not adjusted for sex as this was non-


















Log Income (per Log $) 1.69 
[0.53, 2.85] 
0.005 
Not adjusted for log income as this was 






Not adjusted for log income as this was 
non-significant in univariate model 







Section 4.5. Discussion  
In our analyses of cross-sectional NHANES data from two time points, 1988-
1994 and 2007-2010, we observed an association between warmer temperatures and 
lower lung function in study populations representative of the U.S. non-institutionalized 
population. The effect was modest in both populations with a 0.7 and 1.0 percentile point 
FEV1 decrease for every 10°F increase in mean annual ambient temperature in the 
NHANES III and NHANES 2007-2010 populations, respectively. We had previously 
reported an association between lower lung function and warmer ambient temperatures in 
several independent samples of individuals with cystic fibrosis in the United States and 
Australia.44 We previously estimated that a hypothetical 18 year old white male with 
cystic fibrosis (Height: 175 cm) with an FEV1 of 73.5% predicted who lived in a cold 
climate would be expected to have an FEV1 of 66.1% predicted if he resided in 30 degree 
(°F) warmer climate, which equates to approximately 2.5 percentile point decrease in 
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lung function being associated with a 10°F increase in mean annual ambient temperature, 
or greater than the 0.7 and 1.0 percentile point decreases seen in the general population. 
Taken together these results suggest that climatic temperatures may be associated with 
lung function in all individuals with a perhaps a more prominent effect in individuals 
with lung disease. 
This difference may reflect that same factors operating in the general population 
that decrease lung function with warmer temperatures may be more potent on a 
background of cystic fibrosis, or conversely, in addition, to the factors operating in the 
general population, individuals with cystic fibrosis living in warmer climates may have 
other factors impacting their lung function. Of note, we did previously describe that 
certain respiratory pathogens (Pseudomonas aeruginosa) in cystic fibrosis do mediate a 
portion of the association (6-22% of the association) between lung function and 
temperature in cystic fibrosis. As P. aeruginosa does not typically cause respiratory 
illnesses in healthy individuals, this would be an example of a factor operating in cystic 
fibrosis and not the general population. 
There are a number of limitations to this study. Specifically, there are limitations 
with regards to location of the NHANES participants. First, participants may reside in 
multiple locations over their lives, and it is unknown whether interactions between 
climate and age exist, specifically whether exposure at particular ages has greater 
consequences. Second, NHANES does sample from selected geographic regions 
throughout the United States, and the geographical distribution of participants may not be 
representative of the United States as a whole. Another limitation relates to our 
measurement of temperature. In order to minimize year-to-year variation in temperature, 
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we utilized a 30 year average. It may be that increased temperatures at certain times of 
the year (e.g., summer) may have greater effects on health.106 Other limitations included 
potential confounding factors that we were unable to assess, such as physical activity, 
allergens, and air pollution.100,107,108  
Our findings suggest that temperature may have a modest influence on lung 
function in the general population, although the mechanisms behind such an association 
remain unclear. While the influence may be modest in the general population, the effect 
size of the association may be greater in populations with respiratory disease, such as 
cystic fibrosis, which may have ramifications for other obstructive respiratory disorders, 
such as asthma and COPD. Although the average increase in temperature with climate 
change may be small, it may still lead to an increase in overall respiratory disease burden 




CHAPTER 5. CONCLUSIONS 
Section 5.1. Introduction 
Respiratory diseases, both acute and chronic, are responsible for significant 
morbidity and mortality in both the developed and developing world. Pneumonia is the 
most common cause of death in infants and young children under the age of 5 
worldwide.109 The most common respiratory disease, asthma, will affect 100 million 
people worldwide by 2015 and COPD is predicted to become the third leading cause of 
death by 2030.110 Although potent risk factors for the development and severity of 
respiratory diseases have been identified, such as tobacco smoke exposure and air 
pollution,111 the development of most respiratory disorders remains a complex blend of 
genetic and environmental factors. Understanding the factors that impact respiratory 
diseases and their interactions (i.e., gene-gene, gene-environment, environment-
environment) is an important first step in ameliorating the morbidity and mortality that 
accompanies them. 
Another key issue in understanding the epidemiology of diseases is to also 
recognize changing patterns of disease so as to deploy resources more efficiently. For 
example, the prevalence of asthma among children in the United States doubled between 
1980 and 1995, and continued to rise through 2009, although the reasons for this are not 
entirely clear.112 Factors that lead to disease may also change over time. For example, 
ongoing public health campaigns and efforts to decrease smoking will undoubtedly lead 
to less smoking-related disease.113 Another environmental factor which is anticipated to 
change in the upcoming decades is climate, specifically global warming.114 In fact, 
69 
 
climate change may be the “biggest global health threat of the 21st century.”115 The 
World Health Organization has already estimated that climate change over the past 30 
years is claiming over 150,000 lives annually.45 
Temperature has been recognized a risk factor for worse outcomes in respiratory 
diseases.99 Notably, acute respiratory events and exacerbations of existing respiratory 
disease are more likely to occur during times of temperature extremes. With heat waves 
and cold snaps, an increased frequency of exacerbations and/or deaths has been observed 
in asthma and COPD.100-102 However, there are limited data on how climate affects long-
term trajectories of common diseases. One potential disease model for studying the 
effects of climate on respiratory disease is cystic fibrosis (CF).  We previously 
demonstrated that lower lung function is associated with warmer annual ambient 
temperatures in 3 independent populations of subjects with cystic fibrosis, including 2 
populations in the United States and a third in Australia.44  
The mean ambient temperature changes associated with anthropogenic global 
warming may be modest, 0.3-1.7°C under the lowest emission scenario and 2.6-4.8°C 
under the highest.114 However, in a hypothetical subject with CF, there would be a 0.45 
percent predicted decrease in lung function (FEV1) for every 1°C increase in mean 
ambient temperature, which could potentially equate to an additional 1-2 years of 
survival based on current population-based estimates of lung function decline in CF using 
the highest emission scenario.116 However, the mechanism for this association between 
climate (i.e., ambient temperature) and long-term lung function in CF is not known, nor is 
it known whether this phenomenon exists in other populations, including the general 
population without respiratory conditions. 
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CF serves as an excellent model for studying the effects of climate on respiratory 
diseases, owing to a lower likelihood of disease misclassification as it is well-
characterized, highly penetrant Mendelian disorder with a causative gene that has been 
known for over 25 years.1 Effects on lung function due to environmental exposures such 
as temperature may be magnified in a host predisposed to more rapid lung function 
decline. In addition, dense, longitudinal clinical information is collected routinely every 
three months for the entire lifetime of people with CF. Despite being a single gene 
disorder, CF lung disease remains a complex trait as patients with identical mutations 
may have dramatically different lung function,2-4 implying the involvement of factors 
other than the CFTR gene itself. Family-based studies by our group and others comparing 
lung function between monozygous twins (who share 100% of their genes) and dizygous 
twins and siblings (who share 50% of their genes) suggest ~50% of variation in CF lung 
disease can be attributed to modifier genes and ~50% to environmental modifiers.29,30 
This allows for the possibility of studying environment-environment and/or gene-
environment interactions with regards to climate. 
A number of environmental factors that are associated with lung function (and 
could interact with climate) have been identified in the literature, including secondhand 
tobacco smoke,33-37 household income,39,70,71 occupation,117 health insurance status,39-42,44 
parental education levels,39 adherence to medical therapies,118 exercise,119-124 colonization 
with specific respiratory pathogens,8-15 and air pollution.38 Likewise, several replicated 
genetic loci have been identified that could interact with climate, which include two loci 
(chromosomes 11p13 and 20q13.2) identified through genome-wide association and 
linkage studies by the North American CF Modifier Consortium,52 and polymorphisms in 
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the mannose binding lectin (MBL2) gene,53 the transforming growth factor beta-1 
(TGFB1) gene,54-58 and in the interferon-related developmental regulator 1 (IFRD1) 
gene.59 Overall, the presence of environmental and genetic modifiers in a readily 
diagnosed chronic lung disease characterized by short-term exacerbations and long-term 
decline makes CF a useful model to study the effects of climate on lung disease. 
This study focused on three aspects of the association between temperature and 
lung function in cystic fibrosis. The first part (Chapter 2) focused on identifying 
environmental mediators of this association, the second part (Chapter 3) focused on 
identifying gene-environment interactions, and the third part (Chapter 4) focused on 
determining whether this association existed in non-CF populations. The mediation 
analyses in the first part of this study ascribed a portion of the association in cystic 
fibrosis to 3 respiratory pathogens. The second part of this study did not identify any 
gene-environment interactions between temperature and selected SNPs that are known 
modifiers of CF lung disease or lung function in the general population. The third part of 
the study confirmed the presence of this association within the general population though 
to a lesser degree; hence, there may be some relationship between lung function and 
temperature implicit in human biology or an unmeasured confounder with a geographic 
distribution similar to that of mean annual ambient temperature. The findings of this 
study have important implications for both individuals with cystic fibrosis with respect to 
their healthcare and the general population with respect to population health and climate 
change.  
Section 5.2. Implications: Cystic Fibrosis 
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Taken together, the results from the first and third parts of this study (Chapters 2 
and 4) could potentially explain 40-83% of the association between lower lung function 
and warmer temperatures in CF and identify some mechanisms that underlie this 
association, although it should be noted that the confidence intervals of the mediation 
analyses are wide. The mediation analyses in the first part of this study ascribe 12% or 
43% of the association in cystic fibrosis to 3 respiratory pathogens, depending on the 
population of CF subjects examined. The third part of the study also confirms the 
presence of this association within the general population with effect sizes of 0.7% and 
1.0% predicted FEV1 decrease for every 10°F increase in mean annual ambient 
temperature in the 2 NHANES general population cohorts to an estimated 2.5% FEV1 
decrease in CF suggests that 28% or 40% of the association seen in CF can be ascribed to 
a mechanism also present in the general population, depending on the NHANES cohort 
examined.  
Combining these estimates, 40-83% of the association between lung function and 
temperature may be ascribed to CF respiratory pathogens or mechanisms also seen in the 
general population, and 17-60% may be accounted for other as-of-yet unidentified factors 
particular to CF. This study did not identify any gene-environment interactions to explain 
the association (Chapter 3), but they still may exist as only a small selection of SNPs 
were tested and this study may be underpowered to detect small effect size interactions.  
With regards to individuals with cystic fibrosis, the results from the first part of 
this study suggest that where patients reside impacts outcomes. Specifically, infection 
rates, either prevalence of organisms on respiratory cultures or incidence of initial 
infection, are not constant across the United States. The geographic stratification of 
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respiratory pathogens in CF is not unexpected given geographic distribution patterns of 
many infectious organisms. Recognizing differences in infection rates has ramifications 
for allocating resources in CF care and different approaches to care itself. 
Different infection rates geographically should have an impact on benchmarking. 
In recent years, there has been increased interest in following health outcomes on a 
population level among policy-makers and healthcare payers among others.125 The U.S. 
CF Foundation, which accredits CF care centers in the United States and 
promotes/spearheads best care practice efforts, has been comparing a variety of clinical 
outcomes on a population-basis between CF care centers, including lung function. The 
work in this study suggests that comparisons of centers may need to be weighted based 
on geographic location as there may be factors dictating respiratory pathogen prevalence 
and lung function that are macro-environmental factors outside of their control (i.e., 
ambient temperature).  Likewise, payers of healthcare who reimburse under a capitated 
system whereby providers receive a lump annual sum to care for a population of patients 
may need to reimburse at a higher rate per patient for healthcare providers in warmer 
climates, perhaps owing to lower lung function and higher prevalence of certain 
respiratory pathogens.   
In terms of CF management, the implications revolve around the earlier diagnosis 
of the presence of infectious organisms. Specifically, patients living in warmer climates 
may acquire certain respiratory pathogens at earlier ages, leading to a more rapid rate of 
lung function decline at an earlier age. Often with initial acquisition of certain respiratory 
pathogens in CF, including P. aeruginosa, eradication is possible,126 thus surveillance via 
respiratory cultures may need to be more frequent to detect initial acquisition as early as 
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possible, or eradication and prevention may need to be more aggressive in clinics located 
in warmer climates. It should be noted that it also may be more difficult to eradicate or 
treat these respiratory pathogens in warmer climates, and perhaps longer treatment course 
of antimicrobial therapies could be warranted. 
Our results may have implications for multi-center clinical research studies as 
well. For studies that are conducted across a diverse geographic area, as results may need 
to be adjusted for climatic variation. This may affect studies where the exposure of 
interest is also geographically distributed (i.e., exercise), otherwise false positive or 
negative results may be seen depending on whether studied exposure correlates or 
inversely correlates with temperature. Additionally, multi-center studies that are 
randomized by center may also be affected if there are unbalanced differences in 
temperature between sites as a whole. Strategies to address this include adjusting for 
temperature in analyses and/or randomizing by subject instead of by study site. 
In addition to examining the infections as an environmental mediator between 
temperature and lung function, this study also tested for gene-environment interactions 
between temperature and previously replicated non-CFTR gene modifiers of CF lung 
disease and gene modifiers of lung function in the general population. As previously 
stated, family-based studies suggest ~50% of variation in CF lung disease can be 
attributed to modifier genes,29,30 but significant loci within a GWAS study only explain 
an estimated 4-46% of the variability of CF lung function,52 thus gene-environment 
interactions may explain the unexplained variation seen in CF lung disease.127 In the 
second part of this study we tested for gene-environment interactions in several replicated 
loci of CF lung disease52-59 and several modifiers of lung function replicated in the 
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general population.60-63 However, regression-based testing did not identify any significant 
gene-environment interactions for any of the tested SNPs after correction for multiple 
testing. It should be noted that only a limited number of SNPs were tested, and a genome-
wide study may identify an interaction(s). In addition, given that larger populations are 
frequently needed to identify gene-environment interactions compared to identifying 
simply loci of interest or an environmental exposure of interest,128 more precise 
quantification of the environmental factor of temperature may be required to improve the 
power to detect an interaction.  
Section 5.3. Implications: General Population 
In the third part of this study we tested the hypothesis that mean annual ambient 
temperature was associated with variation in lung function in healthy individuals using 
cross-sectional lung function (FEV1) in healthy non-smokers in the United States from 
two separate cohorts from the National Health and Nutrition Examination Survey 
(NHANES). We observed an association between warmer temperatures and lower lung 
function in study populations with an effect in both cohorts, specifically, a 0.7 and 1.0 
percentile point FEV1 decrease for every 10°F increase in mean annual ambient 
temperature in these 2 cohorts. Thus, assuming a 30°F difference in mean annual ambient 
temperature between colder northern regions in the continental United States and the 
warmer southern regions, individuals in warmer regions could have lung function that 
was 2.1-3.0 percentile points lower on average compared to those living in colder 
regions. This effect size was more modest compared to effect seen with reported tobacco 
use in both NHANES populations. In the NHANES III cohort, the percent predicted 
FEV1 was 5.9 percentile points lower in those reporting tobacco use (n=4773) compared 
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to those who did not (n=15,927; t-test p value<0.001). Likewise, in the NHANES 2007-
2010 cohort, the percent predicted FEV1 was 6.4 percentile points lower in those 
reporting tobacco use (n=2427) compared to those who did not (n=9849; t-test p 
value<0.001). 
With regards to the general population, the mechanism behind this association of 
lower lung function and warmer ambient temperatures remains unclear. It is possible that 
ambient temperature has a direct effect on lung function. For example, pulmonary 
function testing (FEV1) in subjects with and without asthma can be affected by variation 
in temperature and humidity within calibrated environmental chambers.129 Alternatively, 
the association may be mediated through another exposure such as exercise or indoor air 
pollution, which may be subject to regional differences, possibly owing to outside 
ambient temperature.130,131 Additionally, it is possible that a confounding factor could 
lead to varying lung functions locally. For example, living in an urban area may lead to 
exposure to a higher mean annual ambient temperature compared to living in the same 
geographic spot if it were rural, and living in an urban area could also lead to greater 
exposure to air pollution, which adversely affects lung function.96,97,132  
Another confounding factor may be the geographic distribution of respiratory 
pathogens; an increased incidence of respiratory infections in particular regions may lead 
to lower lung function for the population as whole even if only a limited number of 
people are affected. For example, limited data on the proportion of MRSA isolates among 
all S. aureus isolates suggests that there may be geographical trends in the distribution of 
the proportion of MRSA isolates from S. aureus isolates in the United States and 
Europe.133,134 Lastly, given that the effect size of the association is greater in a lung 
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disease such as cystic fibrosis compared to the general population, it is possible that a 
greater effect size is also present with other lung diseases. While we attempted to exclude 
the most common chronic respiratory disease from the NHANES study populations in the 
third part of this study, it is possible that individuals with lung disease remain in the study 
population. If these individuals were geographically distributed such that certain 
respiratory diseases other than asthma (e.g., COPD) or environmental allergies were more 
prevalent in warmer climates, then this could have influenced our results.135 
The implications on public health of our findings may be of increasing import in 
the future. As previously mentioned the mean ambient temperature changes associated 
with anthropogenic global warming may be 0.3-1.7°C under the lowest emission scenario 
and 2.6-4.8°C under the highest.114 Thus, assuming the lowest emission scenario 
temperature change (0.3°C) and the lower lung function change with temperature 
(0.7%/10°F), then the average lung function decrease would be 0.04 percentile points. 
Conversely, assuming the highest emission scenario temperature change (4.8°C) and the 
larger lung function change with temperature (1.0%/10°F), then the average lung function 
decrease would be 0.86 percentile points. While these are very modest changes on the 
population level, it may still lead to an increase in overall respiratory disease burden as it 
is likely that some individuals may be more susceptible to increases in ambient 
temperatures. Specifically, this may still have ramifications for obstructive respiratory 
disorders, such as asthma and COPD,100,136 where the effect size is likely greater. 
Certainly for cystic fibrosis, given our observations that warmer temperatures were 
associated with several respiratory pathogens, it is possible that global warming may lead 
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to a higher prevalence of specific pathogens among individuals with CF, and more rapid 
declines in lung function. 
Section 5.4. Strengths and Limitations 
This study has several strengths, including a well-characterized primary 
population (CF Twin-Sibling study) with respiratory, infectious, and genetic data that 
was used for the first two parts of the study, which focused on CF. The replication 
population for mediation with CF respiratory pathogens included the largest available 
database in term of numbers of participants with CF. The NHANES cohorts used for the 
third part of this study represent one of the largest databases of spirometric data, and has 
also been used as a standard reference population.46,103 Spirometry is a commonly used 
measure of respiratory health, and lung function testing in patients with CF is generally 
robust with multiple tests performed annually with routine clinical care. The NHANES 
spirometric protocols are standardized with robust analysis algorithms.137 
Our study also had several limitations, the most notable being the potential for 
misclassification bias by geographic location as both individuals with CF and NHANES 
participants move over the course of their lifetimes. Although subjects may reside in 
multiple locations over a lifetime, lung function from the most recent year of data and 
each subject’s last known location were used to minimize this uncertainty. Furthermore, 
in a prior study we found that 79.5% of the CF Twin-Sibling Study subjects live within 
the state in which they were born with another 8% living within an adjacent state 
(n=1313).44 However, it is unknown whether interactions between climate and age exist, 
specifically whether exposure (i.e., location) at particular ages has greater consequences. 
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It should also be noted that NHANES does sample from selected geographic regions 
throughout the United States, and the geographical distribution of participants may not be 
representative of the United States as a whole. Unfortunately, due to CDC restrictions on 
the use of data identifiers, we were unable to confirm the geographic distribution of 
NHANES participants.  
Another limitation is the possibility of unmeasured confounders. For the first part 
of this study, which focused on respiratory pathogens, P. aeruginosa has been 
characterized as a highly diverse species,82 and geographic variation in MRSA strains has 
been documented.83  Thus it is possible that more virulent strains are geographically 
distributed in warmer climates by chance alone, and we did not account for strain 
differences. Likewise, the presence of non-tuberculous mycobacteria in CF respiratory 
cultures has been associated with unmeasured factor of vapor pressure, but not ambient 
temperature.84 For all three portions of the study, other potential confounding factors that 
we were unable to assess include physical activity, allergens, and air pollution.100,107,108 
For example, there may be an interaction between air pollution and temperature,100 which 
was unaccounted for in our model.  
Measurement error, especially for temperature and infection, is another concern. 
While the measurement of pulmonary function may be fairly robust, our temperature 
measurement was a coarse measurement. Ambient temperature was estimated for 
individuals based on residential postal zip codes, but this may not be the actual 
temperature subjects were exposed to. Also, in order to minimize year-to-year variation 
in temperature for the purposes of study design, we utilized a 30 year average, but it may 
be that increased temperatures at certain times of the year (e.g., summer) may have 
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greater effects on health.106 For first part of the study which incorporated infection data, it 
should be noted that these data were obtained from clinical specimens largely obtained 
through sputum samples and throat swabs; the latter, in particular, may not accurately 
represent lower airway flora, especially at younger ages.18 However, poor quality of 
culture data would likely bias our results to the null, rather than leading to positive 
associations. Also, our use of retrospective culture data may under- or overestimate the 
prevalence of respiratory pathogens depending on reporting biases by CF care centers 
who may not report all culture data to the CF Foundation.  
Another potential measurement error is the use of imputed SNP data in the second 
part of this study. However, the correlation between observed and imputed alleles with a 
similar 660K platform that was utilized is 0.93, suggesting that imputing a marker for 
1000 subjects would provide similar data to genotyping that marker for 930 subjects.64,65 
Lastly, even though the measurements of lung function were collected using standardized 
protocols, it is critical to note that lung function measurements were cross-sectional 
owing to study design considerations of linking location and lung function temporally; 
however, a single value may not necessarily reflect the baseline lung function. This may 
be particularly the case for individuals with cystic fibrosis who have respiratory 
exacerbations with transiently lower lung function.21 
Lastly, our models may not accurately represent the association between 
temperature and lung function. Adjusted clustered linear regression (generalized 
estimating equations) was utilized as the primary mode of analysis for all three parts of 
this study, and it is possible that the relationship between temperature and lung function 
was not linear. Additionally, our model for the first part of this study assumes that the 
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mediation variables of infection act upon the outcome variable of lung function, whereas 
it is also possible that more severe lung disease can lead to an increased propensity for 
infections. Our mediation analyses also had wide confidence intervals, so it is possible 
that we markedly underestimated or overestimated the impact of mediation with 
infectious pathogens on the association between temperature and lung function. It is also 
possible that individuals with CF may have polymorphisms in modifier genes affecting 
infection acquisition/colonization that are geographically distributed owing to founder 
effects or immigration patterns. Likewise, in the second part of the study, we assumed 
that gene-environment interactions occurred through additive models, rather than 
dominant or recessive. It is also possible that the association between temperature and 
lung function is mediated by one of the studied SNPs through dominant or recessive 
models, which was not employed in this study as we felt an additive model to be more 
agnostic than non-additive models. 
Section 5.5. Future Directions 
This study provides some evidence regarding potential mechanisms underlying a 
relationship between ambient temperature and lung function with several avenues of 
future research. The first avenue of research could focus on CF patients. Although 30-
83% of the association between temperature and lung function can be attributed to 
respiratory pathogen distribution and general population effects, this still leaves work to 
be done identifying other factors. In addition, work could also focus on why respiratory 
pathogens are more prevalent in warmer climates among CF patients, such as whether 
this is due to an increased presence of these organisms in warmer climates (e.g., larger 
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reservoirs) or increased susceptibility to infection or colonization in warmer climates due 
to pathogen-specific or host-specific factors.  
Although studies will be observational by nature as individuals cannot be 
randomized by climate, improved data regarding location over time could be very 
helpful. Specifically, data that is linked to an individual’s location over a lifetime could 
parse out the effects of specific geographic regions and or age-climate interactions. 
Alternatively, studying outcomes in subgroups of individuals who have moved from a 
warmer climate to a colder climate or vice versa may provide more power to detect some 
of these effects, although there may be other confounding effects of environment. For 
example, many individuals may move upon entering adulthood to attend educational 
institutions some distance from their childhood residence, but the different environment 
of college may introduce additional effects.29 
It is also possible that temperature may have an effect on CFTR function itself 
through the inhaled air temperature acting upon CFTR-bearing respiratory epithelial 
cells. There is some evidence that at least the most common mutation of CFTR (F508del) 
may have thermal instability.138,139 Worse protein function at warmer temperatures could 
lead to worse disease outcomes as certainly functional classes are associated with 
differences in phenotype and mortality rates.140 One potential in vivo measurement of 
CFTR function is sweat chloride.141 Advances in technology may lead to wearable sweat 
chloride monitoring devices in the near term future.142,143 Such devices would allow for 
real-time measurement of a biomarker for CFTR function under differing ambient 
temperature conditions, albeit in a different tissue than respiratory epithelium.  
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A second avenue of research could focus on the general population, including 
confirming this association in other regions of the world. Ideally, these regions would 
have similar healthcare systems across the population to be studied to minimize this 
source of variation. Given that the United States has an ethnically diverse population and 
lung function can be adjusted for race/ethnicity, studies may not need to be carried out in 
an ethnically homogenous population. More importantly, future research would also 
begin to identify potential mechanisms and confounders for this association in the general 
population. Some factors can be excluded, such as active smoking which was controlled 
for by excluding active smokers, but other factors will need to be tested for such as 
secondhand smoke, obesity, and/or exercise. As an example, obesity may be associated 
with temperature extremes as hot summers and cold winters may discourage exercise,144 
and obesity may also affect lung volumes.145 As one limitation of our study was the use 
of cross-sectional lung function data, further research could examine longitudinal data. 
Similar to the above proposed research for CF, data that is linked to an individual’s 
location over a lifetime could parse out the effects of specific geographic regions and or 
age-climate interactions, which may be more important in the general population, who 
may be more mobile than individuals with CF. 
A third avenue of research could focus on other respiratory diseases. Although a 
larger effect size of temperature on baseline lung function was seen in individuals with 
cystic fibrosis versus the general population, it is unknown whether this would also hold 
true with the baseline lung function of other respiratory diseases. If a larger effect size 
was seen in some or all other respiratory diseases, this would imply that individuals with 
respiratory disease in general are more susceptible to the effects of temperature, and 
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hence climate change. Alternatively, if the effect size in other respiratory diseases is 
similar to that of the general population, that would imply that unique mechanisms are 
present in cystic fibrosis that alter outcomes in warmer temperatures. The presence of 
large multicenter disease-specific studies may lend itself to studying this question (e.g., 
the COPDGene study146). 
Lastly, research could still continue to focus on gene-environment interactions in 
cystic fibrosis with ambient temperature. Although, we did not identify an interaction 
within the study population for the second part of the study, only a limited number of 
SNPs were tested, and a genome-wide study may identify an interaction(s). In addition, 
given that larger populations are frequently needed to identify gene-environment 
interactions compared to identifying simply loci of interest or an environmental exposure 
of interest,128 more precise quantification of the environmental factor of temperature may 
be required to improve the power to detect an interaction. Specifically, instead of 
utilizing a mean annual ambient temperature as was done in this study, lung function 
could be linked to the temperature at the time lung function was performed, which could 
be done at least by month and year; this increased granularity may also provide better 
estimates of effect size for other temperature-related analyses.  
An alternate approach to studying gene-environment interactions may be to utilize 
variable trajectories using mixed modelling approaches with multiple data points for both 
temperature and lung function. Although many traditional gene-environment interaction 
analyses have treated both the environmental factor(s) and outcome measure as a fixed 
measure obtained at a single time point, such an approach may not capture the full 
variability associated with a chronic disease with a declining health status or 
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environmental exposures that change over a lifetime. Equally importantly, genome-wide 
approaches that phenotype an individual with longitudinal data should increase statistical 
power over phenotyping an individual with data from a single time point.147 
In conclusion, we previously found that warmer ambient temperatures are 
associated with lower lung function in cystic fibrosis, and have now observed evidence of 
partial mediation of this association through respiratory pathogens and also observed this 
association in the general population. Further research is required to confirm causality 
and determine mechanisms underlying this relationship as it may have increased 
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